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Huntington's Disease (HD) belongs to the CAG repeat family of neurodegenerative 
diseases and is characterized by the presence of an expanded polyglutamine (polyQ) 
repeat in the huntingtin (htt) gene product. PolyQ-expanded htt accumulates within large 
aggregates in various subcellular compartments, but are more often localized within the 
nucleus. The sequestration of proteins essential to cell viability may be one mechanism 
that accounts for toxicity generated by polyQ-expanded proteins. Nuclear inclusions 
containing polyQ-expanded htt recruit the transcriptional cofactor, CREB-binding protein 
(CBP). PolyQ toxicity appears to involve alterations of gene transcription and reduced 
neuronal cell viability. In the HT22 hippocampal cell line, we found that toxicity within 
individual cells induced by polyQ-expanded htt was associated with the localization of 
the mutant htt within either nuclear or perinuclear aggregates. However, in addition to 
CBP recruitment, we found that CBP ubiquitylation and degradation can be selectively 
enhanced by polyQ-expanded htt. Thus, selected substrates may be directed to the 
ubiquitin/proteasome-dependent protein degradation pathway (UPP) in response to 
polyQ-expanded htt within the nucleus. While both the polyQ domain and the histone 
acetyltransferase domain (HAT) of CBP have been found to interact with polyQ-
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expanded htt, deletion of either domain does not affect its enhanced degradation in the 
presence of polyQ-expanded htt in HT22 cells. Thus, enhanced degradation of CBP in 
cells expressing polyQ-expanded htt may not involve a direct interaction between CBP 
and htt. It seems likely specific enzymes in the UPP may be activated by htt and 
selectively target proteins such as CBP for degradation.  
 
Since molecular chaperones are found in the aggregates containing polyQ-expanded 
proteins, misfolding of polyQ-expanded proteins may play a key role in polyglutamine 
disease pathogenesis. In a number of some studies, HDJ-2, a member of DnaJ family 
molecular chaperones, was found to reduce aggregation and toxicity induced by polyQ-
expanded proteins. In contrast, we show that HDJ-2 is unable to rescue aggregate 
formation of polyQ-expanded htt in transfected HEK293 fibroblast cells, nor is it 
recruited into these aggregates in vivo in a HD transgenic mouse model. Thus, molecular 
chaperone effects on polyQ-expanded protein induced toxicity could be cell-type specific 
or influenced by the developmental state of the culturable cells. These factors must be 
considered in any attempts to use chaperones as potential therapeutic targets in 
polyglutamine diseases.  
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CHAPTER I: INTRODUCTION 
 
I. NEURONAL CELL DEATH 
 
1. Apoptosis and Necrosis 
 
In 1972, Kerr et al. described and compared two types of cell death, necrosis vs. 
apoptosis in liver cells (1). Necrosis generally occurs in response to acute injury. Necrotic 
cells swell and burst, releasing cellular components to the extracellular space and causing 
inflammation to surrounding tissues (2). In contrast to necrosis, apoptosis has its unique 
morphological features such as cell shrinkage, membrane blebbing, chromatin 
condensation and DNA fragmentation (2). Apoptotic cells release no harmful material to 
the extracellular space and therefore restrict cell death only within themselves (2). Table 
1 shows the major differences between apoptosis and necrosis. Among those features, 
apoptosis requires new gene expression and protein synthesis, which indicates that it is a 
well-programmed intrinsic suicide process (also see later for details). 
 
Apoptosis, also named Programmed Cell Death occurs in many organisms. It is both a 
physiological phenomenon that occurs during normal development and induced by 
various disease conditions. In this chapter, only apoptosis in neuronal systems will be 
discussed.  
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Table 1: Comparison between apoptosis and necrosis  Adapted from (2) 
 Necrosis Apoptosis 
   
Cytoplasmic 
organelles 
Swelling of all cytoplasmic 
compartments due to altered 
transmembrane ion influx 
Cytosol condensation without changes 
in ion influx 
   
Nucleus Nuclear membrane rupture Membrane blebbing, condensation of 
nucleus 
   
chromatin Loose aggregates of chromatin Internucleosomal DNA cleavage, DNA 
fragmentation and condensation 
   
ATP Depletion of cellular energy (ATP) ATP dependent 
   
Macromolecular 
synthesis 
Decreased RNA and protein 
syntheses 
New RNA and protein syntheses 
dependent 
   
Affect on 
surrounding cells 
Affects surrounding cells by 
releasing toxic cellular components. 
Death within scattered individual cells 
   
 Passive process Active process 
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Neuronal apoptosis can be induced by a variety of stimuli such as neurotropic factor 
withdrawal, oxidative stress, DNA-damage agents, neurotransmitter release, irradiation 
and oxidative stress (2). In fact, the same types of stimuli may cause both apoptosis and 
necrosis dependent on the dose and duration of the damaging stimuli (3). For example, 
low dose of NMDA activation may induce neuronal apoptosis while high dose may cause 
necrosis (4, 5). In models of both acute neuronal injuries such as stroke and chronic 
neurodegenerative disease such as Parkinson’s Disease (PD), neuronal cell death may 
exhibit features of either apoptosis or necrosis or a combination of both (6, 7).  
 
In addition to utilizing the morphological changes specific to apoptosis, there are several 
ways to identify the presence of apoptosis. One is the Tdt-mediated dUTP-biotin nick end 
labeling (TUNEL). TUNEL labels the 3’ end of single or double stranded cleaved DNA, 
which may represent DNA fragmentation in the apoptotic process (2). Another way is to 
detect ladder-type DNA fragmentation by gel electrophoresis that results from DNA 
cleavage at the internucleosomal linker region (2). However, both the TUNEL staining 
and DNA electrophoresis can not reliably distinguish apoptosis from necrosis as they can 
be positive in some cells with necrosis (2, 8). False positive and negative results may 
occur under certain circumstances (2). Therefore, to confirm the presence of apopotosis, a 
combination of multiple methods must be used which often target molecular markers of 
apoptois (9) (see below).  
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2. Apoptotic proteins and apoptotic pathways 
 
Apoptosis is a complicated process and involves multiple pathways. While numerous 
proteins have been shown to play a role in apoptosis, several groups of proteins are most 
important. For example caspases are a family of cysteine proteases that cleave their 
substrates with signature specificity after aspartic acid residues (10). They are apoptotis- 
specific proteases. There are more than ten members of the caspase family that form an 
apoptotic cascade to execute apoptosis in respond to death signals (Figure 1) (11).  They 
can be divided into two categories: upstream initiator caspases and downsteam 
executioner caspases. Initiator caspases are activated in response to apoptotic stimulti and 
cleave other caspases (11). For example, caspase 9 is an initiator caspase that can be 
activated by the death signals through a relay initiating from mitochondria (see later). 
Activated caspase 9 in turn cleaves downstream caspases. For example, it cleaves 
procaspase 3 after a specific aspartic acid residue into a short form that is the active form 
of caspase 3 (12). Caspase 3 is an example of downstream executioner caspases that 
cleaves cellular protein substrates in various subcellular compartments. Activated caspase 
3 may then translocate into the nucleus and cleave substrates such as lamin A, poly(ADP-
ribose) polymerase (PARP) and DNA fragmentation factor (DFF) 40 and 45 (10). The 
active forms of DFF have DNase activity. DFF 40 and 45 act on DNA causing DNA 
fragmentation and chromatin condensation which are the hallmarks of apoptosis (10). 
The importance of caspase 3 in neuronal apoptosis is demonstrated through genetic 
studies. Caspase-3 knockout mice exhibited hyperplasia and disorganized cellular 
deployment in the brain (13).  
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Another important family of proteins involved in neuronal apoptosis is the Bcl-2 family 
proteins. They regulate apoptosis by affecting cytochrome c release from mitochondria. 
Cytochrome c release to the cytosol activates pro-caspase 9 and then initiates an 
apoptotic cascade.  Bcl-2 and Bcl-XL are important anti-apoptotic proteins, while Bak, 
Bim, Bad and Bax are pro-apoptotic (10). Bcl-2 is a negative regulator of cytochrome c 
release and therefore is anti-apoptotic. Transgenic mice that overexpress Bcl-2 showed 
increased brain size resulting from decreased apoptosis (14, 15). In contrast, Bax is a pro-
apoptotic Bcl-2 family protein. Bax knock-out mice show significantly decreased 
apoptosis of synapse-bearing neurons whose survival are neurotrophic factor-dependent 
(16). In addition to caspases and Bcl-2 family proteins, many other proteins also play 
important roles in regulating apoptosis such as transcription factors that discussed later 
(also see Figure 1). 
 
Neuronal apoptosis can be triggered by both intracellular and extracellular signals. As 
shown in Figure 1, extracellular apoptotic signals convey through a FAS/FADD/Caspase-
8 pathway to activate caspase 3. Intracellular signals activate caspase-3 through a 
Cytochrome C/Apaf-1/Caspase-9 pathway (10).   
 
3. Apoptosis and transcription 
 
Apoptosis generally is dependent on new gene transcription that results in new mRNA 
and protein synthesis. Apoptosis can be blocked by inhibitors of macromolecular 
synthesis such as actinomycin D, an inhibitor to transcription and cycloheximide, an  
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Figure 1: Some important pathways regulating apoptosis  
Apoptosis is regulated by multiple pathways. The two main apoptotic pathways acting 
through the activation of caspase cascade are the FAS/FADD/Caspase-8 death receptor 
dependent pathway and Cytochrome c/Apaf-1/Caspase-9 mitochondria dependent 
pathway. These pathways are also regulated by other signaling cascades or proteins such 
as the JNK pathway, the ERK pathway and p53. 
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inhibitor to protein synthesis (17). For example, Sakhi et al. showed that the glutamate 
analogue kainic acid induced apoptosis of adult rat central nervous system where p53 
transcription is elevated. Cycloheximide treatment to these rats resulted in both an 
inhibition of apoptosis and p53 synthesis (18). Gobble et al. showed that moderate 
amount of irradiation caused apoptosis to rat cortical neuron that was blocked by 
cycloheximide treatment (3) (also see later). 
 
What are the genes that are activated during apoptosis? The activity of some transcription 
factors are increased during apoptosis which results in the new synthesis of “apoptotic 
genes” such as DNA damage responsive genes and DNA repair proteins (3). For 
example, the c-Jun NH2-terminal kinase (JNK) pathway may mediates apoptosis in a 
transcription dependent manner (2). JNK is activated upon phosphorylation by upstream 
kinases, and it in turn phosphorylates and activates c-jun. c-jun is a transcriptional factor 
and mediates the transcription of several apoptotic genes such as cyclin D1 (19). p53 is 
also a transcription  factor that can activate many apoptotic related genes (20). One target 
of p53 is Bax, which plays an important role in regulating mitochondrial cytochrome c 
release to promote apoptosis (20). 
 
In addition to proteins that have pro-apoptotic functions, those that are anti-apoptotic also 
play important roles in neuronal survival and death. Among these proteins are also some 
transcription factors. For example, cAMP response element binding protein (CREB) is a 
well-known transcription factor that has important roles on neuronal function (21). It 
binds to the cAMP response element located within the upstream DNA sequences of a 
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variety of genes. Many of these genes are involved in neuronal function such as 
neuropeptides/neurotransmitters and neuronal growth factors (21). Of particular interest 
to neuronal apoptosis is one of the CREB regulated genes that encodes the Bcl-2 protein, 
which is a key anti-apoptotic factor that regulates the mitochondrial dependent apoptotic 
pathway in a cell (14). Riccio et al. used a sympathetic neuron model and demonstrated 
that the increase of neuronal survival by neurontrophins was due to the expression of 
certain prosurvival genes. The transcription of these genes including Bcl-2 is dependent 
on CREB family transcription factors (22).  
 
4. Apoptosis during neuronal development and under neuropathological conditions 
 
The study of apoptosis in brain development primarily focuses on the synapse-bearing 
neurons. It is well believed that apoptosis in these neurons occurs in order to facilitate 
appropriate neuron-target cell innervation (10). Presynaptic neurons that can not find a 
target cell will undergo apoptosis. Target cells once innervated secrete limited amounts of 
neurotrophic factors called neurotrophins, such as nerve growth factor (NGF) and brain 
derived neurotrophic factor (BDNF). Presynaptic neurons that are not exposed to 
neurotrophins at specific times during their development will die through apoptotic 
pathways. This mechanism ensures that the correct amount of neurons will survive to 
provide precise target cell innervation (2, 23). 
 
Apoptosis in the developing brain occurs in pre-synaptogenic neurons (i.e. neuronal 
precursor cells and immature neurons) as well. Apoptosis in these neurons facilitates 
9 
appropriate brain morphogenesis and the removal of damaged neurons (10, 23). In the 
previous section, the function of some important apoptosis related proteins have been 
discussed such as caspase 3 and Bcl-2.  
 
Neuronal cell death also occurs under neuropathological conditions, either acute injury 
such as stroke or chronic neurodegenerative diseases (2). However, as apoptosis is clearly 
identified in brain development by both morphological and molecular methods, evidence 
for neuronal apoptosis under various disease conditions are not very clear. Both necrosis 
and apoptosis may be present simultaneously, and be related to the amount of toxic 
stimuli (3, 9). Morphological changes associated with brain injury are often not quite 
typical of apoptosis (9). Apoptosis in the brain of some neurodegenerative diseases will 
be discussed in detail in the following section.    
 
II. NEURODEGENERATIVE DISEASES 
 
1. Diseases 
 
Table 2 lists some of most common neurodegenerative diseases.  Among them, 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) affect millions of elderly people 
severely and significantly influences the quality of life of the patients and their families. 
Huntington’s disease (HD) is one of polyglutamine-related neurodegenerative diseases 
and affects 1/10,000 people in the United States (24).  
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Table 2: A list of most common neurodegenerative diseases  Adapted from (10, 24, 25) 
Diseases 
 
 Disease 
onset 
 Prevalence 
in US 
 Genetic 
Features 
 Gene  Sites of 
degeneration 
 Symptoms   Inclusions 
and 
Subcellular 
sites 
 Toxic 
protein 
Alzheimer’s 
(AD) 
 senior 
10% 
over 65  
 
 4 million  Sporadic 
& 
genetic 
 APP 
Presenilin1 
& 2 
 Neocortex 
and 
hippocampus 
 Memory 
loss, 
dementia 
impairement 
in other 
forms of 
cognition 
and behavior 
 Extracellular 
plagues 
 
Intracellular 
tangles 
 Aβ 42kd 
 
 
Tau 
Parkinson’s 
(PD) 
 Senior 
1-2% 
over 65  
 1 million  Sporadic 
& 
genetic 
 a-
synuclein 
Parkin 
UCHL1 
PRNP 
 Dopaminergic 
neurons in the 
substantia 
nigra 
 Muscle 
rigidity, 
bradykinesis 
and resting 
tremor 
 Cytoplasmic 
Lewy bodies 
 α-
Synuclein 
Huntington’s 
(HD) 
 30-40  30,000  genetic  Huntingtin 
(htt) 
 Striatum and 
cortex 
 Progressive 
chorea, 
rigidity and 
dementia 
 Nuclear and 
Cytoplasmic 
aggregates 
 htt 
Amyotrophic 
lateral 
sclerosis 
(ALS) 
 40-  20,000  Sporadic 
& 
genetic 
 SOD  Upper and 
lower motor 
neurons 
 Muscle 
atrophy and 
fatal 
paralysis 
 Bunina body  SOD 
Progressive 
supranuclear 
palsy (PSP) 
 Mid-
age to 
eldly 
 15,000    Tau  Striatum, 
cerebellum 
 Early falls 
and 
abnormal eye 
movement 
 Cytoplasmic 
tangles 
(NFT) 
 Tau 
Prion    400  Sporadic 
& 
genetic 
 prion    Psychiatric 
and behavior 
abnormalities 
 Prion plaque  PrPsc 
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2. Common mechanisms underlying the pathogenesis of various neurodegenerative 
diseases 
 
Each neurodegenerative disease is well distinguished from the others in several aspects. 
For example, each of them has distinct symptoms based on the sites of pathogenesis in 
brain. AD mainly affects neocortex and hippocampus which results in cognition and 
behavior abnormalities with little effect on motor function even at very late stages of the 
disease (24). Compared to AD, PD and HD both affect CNS on motor functions at early 
stages of the diseases. PD primarily affects dopaminergic neurons in the substantia nigra  
and causes mainly motor dysfunction such as muscle rigidity, bradykinesis and resting 
tremor at early stages of disease (24). HD is a definite genetic disease and its pathology 
initiates from caudate nucleus striatal neurons which causes an opposite effect on motor 
function compared to that of PD. HD patients suffer progressive chorea at the beginning 
the disease, but later also develop rigidity and dementia resulting from massive damage 
to numerous brain areas (26). 
Despite all the differences, it is increasingly apparent that all of the neurodegenerative 
diseases share common features at both the pathological and molecular levels (24, 27, 
28). A better understanding of these similarities may enable researchers to develop 
effective therapies to treat these diseases. Some of these similarities are discussed below. 
 
2.1 Aggregates: As shown in Table 2, an important feature of many neurodegenerative 
diseases is the presence of intracellular and/or extracellular aggregates that contain 
specific abnormal proteins in each disease. For example, in AD brains, both extracellular 
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plaques and intracellular neurofibrillary tangles (NFT) are detected (25). The 
extracellular plaques contain mostly the 42kD Aβ protein, which is an aberrant 
proteolytic product of amyloid precursor protein (APP). The NFT also contain 
microtubular tau protein (25). In PD, cytoplasmic Lewy’s bodies containing α-synuclein 
are detected in the affected brain area (28). As in polyglutamine diseases, intracellular 
aggregates containing specific proteins encoded by specific diseases genes are considered 
as a hallmark of this group of diseases (27). Aβ, α-synuclein and polyglutamine proteins 
have been found to form compact β-sheet rich structures which are insoluble in the cells 
(27).  
 
Many questions remain about protein aggregates in neurodegenerative diseases. For 
example, how do aggregates form?  Aggregates containing the disease-proteins such as 
Aβ and α-synuclein also recruit ubiquitin, other components of Ubiquitin Proteasome 
Pathway (UPP) and molecular chaperones (29-31). These observations suggest that a 
failure of the cell to refold or degrade toxic proteins may result in their accumulation into 
insoluble aggregates. Toxic proteins in the aggregates may recruit critical factors such as 
transcriptional factors (32). Recruitment of components of UPP into aggregate may 
inhibit the normal functioning of the protein degradation pathway (33). 
 
There is still much debate about the role of these aggregates in toxicity. Some studies 
show that aggregates are intrinsically toxic (33, 34), while other studies suggest that 
aggregation may serve to sequester disease protein and lower the exposure of toxic 
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surfaces to the cell (35). Therefore, aggregation may also be beneficial. A detailed 
discussion of this issue will follow in later sections. 
 
2.2 Proteolysis: In some neurodegenerative diseases, proteolysis of disease proteins from 
their longer precursors is also likely to play a role in neuronal toxicity (27, 36). In AD, 
the 42 kD Aβ protein is a proteolytical cleavage product of an amyloid precursor protein 
(APP) (36). APP is a transmembrane protein and is not toxic. APP can be processed by 
several secretases. Insoluble 42kD Aβ protein is obtained after cleavage of APP by γ-
secretases followed by its translocation to the extracellular space and the formation of 
tangles (37). Several polyglutamine disease proteins including huntingtin, androgen 
receptor (AR) and ataxin 1 also are likely to be more toxic when they are cleaved into 
their truncated forms (38-40). The relationship between polyQ protein truncation and 
toxicity will be discussed in later sections. 
 
2.3 Selectivity: In several of these diseases, such as PD and HD, toxic proteins only 
affect a certain subpopulation of neurons (27). The reason why certain types of neurons 
are particularly prone to pathology in these specific cases is far from understood. 
 
2.4 Apoptosis and other mechanisms: Studies from different neurodegenerative 
diseases reveal that apoptosis may occur in the affected brain areas (2). However, the 
evidence from in vivo studies is not quite strong. For example, results from TUNEL 
staining of PD postmortem brain revealed a large variability (9). Some studies showed 
that about 1% of nigra cells were positive, while other studies showed no TUNEL 
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positive cells (9). This variability can be explained by the limitation of techniques of the 
TUNEL assay. Another explanation of negative or low percentage of apoptosis found in 
PD postmortem brain is that as the chronic disease process takes years to develop, few 
neurons may be undergoing apoptosis at any time point that is examined (2, 9). Bax and 
caspase 3 activation have also been found in PD postmortem brains although only in a 
few neurons (i.e. <3%) (41). Evidence of apoptosis in postmortem brains of in AD and 
HD are not quite clear as well (42, 43). However, in vitro assays such as cell transfection 
are able to demonstrate the presence of apoptosis at the molecular levels with more 
simplicity. Both the FAS/FADD/Caspase-8 pathway and  mitochondria Cytochrome 
c/Apaf-1/Caspase-9 pathway have been shown to play roles in HD, PD and AD (9, 42, 
43). Detailed discussion of apoptosis in HD will follow in the next section. Stressful 
stimuli including oxidative stress, excitatory toxicity, mitochondrial dysfunction and lack 
of sufficient neruotrophic factors may also play a role in triggering neuronal apoptosis 
(2). 
 
3. Protection from toxicity in neurodegenerative diseases: Some therapeutic strategies 
are being developed to target common mechanisms of these neurodegenerative diseases. 
 
3.1 Targeting aggregates directly: In a Tet-regulated conditional HD transgenic mouse 
model, reversal of aggregate formation is followed by the improvement of symptoms 
(44). This study suggests that blocking the expression of aggregates may be beneficial. 
Congo red has been shown to block aggregation formation and reduce toxicity (45). 
Other ways to target aggregates directly include improving the correct-folding of these 
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toxic proteins by overexpression of molecular chaperones (29); or promoting the 
degradation of the aggregates through the activation the UPP (27).  
 
3.2 Targeting cellular proteins that are recruited by the aggregates: Many 
transcriptional factors such as Sp1 and CREB-binding protein (CBP) have decreased 
functions as a result of aberrant interactions with polyQ proteins (46, 47). Recovering the 
functions of these important factors may be helpful to reduce neuronal toxicity induced 
by aggregation (28, 32). As will discuss more detailed later in chapter II, recovery of 
CBP activities by its overexpression or restoring its histone acetyltransferase activity has 
been shown to reduce toxicity in several in vivo and in vitro HD models (47, 48). 
 
3.3 Targeting proteolysis and translocation of toxic proteins: Aβ is a cleavage product 
of APP that moves from the cytosolic membrane to the extracellular space where it forms 
tangles. Futhermore, although full length huntingtin protein is cytoplasmic, the truncated 
form translocates to the nucleus to aggregate. Therefore, blocking truncation and 
translocation may be a useful way to block aggregation and toxicity in some of these 
diseases (28). For example, Wellington et al. showed that htt protein with a mutation at 
the putative caspase 3 cleavage sites was resistant to cleavage and had reduced toxicity in 
neuronal or nonneuronal cells (49). 
 
3.4 Targeting apoptosis: Apoptosis may be the final outcome of affected neurons in all 
of these diseases. Directly targeting apoptosis may also be an efficient treatment (28). For 
example, there have been some studies that used caspase inhibitors to rescue neuronal 
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toxicity in different neurodegenerative diseases (9, 50, 51). See the later sections for 
details.  
 
III. POLYGLUTAMINE DISEASES 
 
1. Introduction: 
 
Polyglutamine diseases are a group of at least 9 neurodegenerative diseases, whose 
disease-proteins all contain an expanded polyglutamine tract (Table 3). HD is caused by a 
CAG expansion in the huntingtin (htt) gene. Kennedy’s Disease is caused by a similar 
mutation in androgen receptor gene. In Dentatorubral pallidoluysian atrophy (DRPLA), 
the disease gene is atrophin 1. Finally there are 5 types of SCAs (1, 2, 3, 6, 7) caused by 
mutations in ataxin genes (27). Recently a new CAG expansion was identified at the 
TATA-box binding protein (TBP) gene in the disease SCA17 (52). In addition to the 
expanded CAG repeat, these diseases share many common features (discussed below).  
  
2. Genetics:  
 
PolyQ diseases are all dominantly inherited diseases with the exception of Kennedy’s 
Disease (SBMA), which is X-chromosome linked recessive inherited. All others are 
autosomal. 
 
2.1 Polymorphism of CAG repeat and its relevance to disease phenotype:  
The CAG repeat has a polymorphism in the normal population. In normal individuals, 
these genes all bear a normal range of CAG expansion. Generally, there is a threshold of 
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Table 3: Polyglutamine diseases  Adapted from (42, 53) 
 
Polyglutamine Repeat 
Diseases 
Disease protein Normal 
glutamine 
repeat 
range 
Pathological 
glutamine 
repeat range 
truncation Physiological 
functions 
Molecular 
weight 
(kDa) 
Nuclear 
localization 
signal 
Huntington’s disease (HD) Huntingtin (htt) 6-35 36-121 YES Unknown 348 No 
Spinobulbar muscular 
atrophy (SBMA) 
(Kennedy’s Disease) 
Androgen 
receptor (AR) 
9-36 38-62 YES Known, 
ligand-
dependent 
transcription 
factor 
99 Yes 
Dentatorubral pallidoluysian 
atrophy (DRPLA) 
Atrophin-1 6-35 49-88 YES Unknown 124 No 
Spinocerebellar ataxia type 
1 (SCA1) 
Ataxin-1 6-44 39-82 NO Unknown 87 Yes 
Spinocerebellar ataxia type 
1 (SCA2) 
Ataxin-2 15-31 36-63 N/A Unknown 90 No 
Spinocerebellar ataxia type 
1 (SCA3) 
Ataxin-3 12-40 55-84 YES Unknown 42 No 
Spinocerebellar ataxia type 
1 (SCA6) 
Ca2+ channel 
subunit 
4-18 21-33 N/A Unknown large No 
Spinocerebellar ataxia type 
1 (SCA7) 
Ataxin-7 4-35 37-306 N/A Unknown 95 Yes 
Spinocerebellar ataxia type 
1 (SCA17) 
TBP -42 47- N/A Transcription 
factor 
42 Yes 
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the number of CAG repeats, only above which will give rise to disease phenotype (27). 
Listed in Table 3, we can see that threshold in most of these diseases is in the range of 
35-45 consecutive CAGs in the repeat (27). Although the exact reason why this range 
will cause the disease is not known, some data suggest that a certain number of 
consecutive glutamine residues cause aberrant conformational changes in the disease 
proteins (54, 55).  The number of the glutamine residues in the disease proteins also 
conspicuously impacts the age of disease onset and progression: the higher the number, 
the earlier the disease onset and the more severe the symptoms (28).  
 
2.2 Disease proteins: Proteins in each of these diseases with a normal range of glutamine 
repeats does not have a clear physiological function except for the AR in Kennedy’s 
Disease (SBMA) and TBP in SCA17. AR is a ligand-dependent transcription factor. 
After binding with hormone it translocates from the cytoplasm to the nucleus and initiates 
transcription of some genes (56). TBP is a critical protein in the basal transcription 
machinery (52). It binds to the TATA box sequence of promoter region of genes which is 
one of the key steps required to initiate transcription.  Disease proteins with normal 
lengths of CAG repeat in other diseases do not have a clear function. Therefore, whether 
these proteins lose normal functions when expanded with a long CAG repeat is difficult 
to be determined. In some following sections, whether a loss-of-normal function or a 
gain-of-toxic function of these proteins contributes to the pathogenesis of polyglutamine 
disease (especially HD) will be discussed in detail.  
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3. Pathology:  
 
3.1 Selectivity of subpopulation of neurons: In nearly all patients with polyglutamine 
diseases, the mutant protein is expressed throughout the central nervous system (CNS). 
However, some regions of the brain tissues are more susceptible to the expression of 
mutant protein than others. Furthermore, in affected areas, neurons are more prone to die 
than glia cells(26, 57). For example, in early stages of HD, striatal and cortical neurons 
are most affected (26). In SCA1, cerebellar Perkinje neurons are the first and mostly 
affected (57). The reasons for this selectivity are not clear yet, but probably depend on 
the function of each specific protein, their normal function in the affected areas and other 
interacting proteins. 
 
3.2 Aggregates (inclusions):  Intracellular inclusions or aggregates have been considered 
as a pathological hallmark of polyglutamine diseases (53).  
 
3.2.1 Subcellular localization of polyQ aggregates: For proteins such as ataxin-1 which 
is normally a nuclear protein, mutant ataxin-1 forms nuclear aggregates in the affected 
neurons (58). For proteins like htt whose full-length wide type version is entirely 
cytoplasmic in the adult brain, aggregates are found in all three compartments of an 
affected neuron i.e. nucleus, perikaryon and processes in affected areas (38). Except for 
SCA2, in which mainly cytoplasmic aggregates are observed (59), all other 
polyglutamine disease proteins form nuclear aggregates (53). Nuclear aggregates may 
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have an impact on some nuclear functions such as transcription (32), while aggregates in 
neuronal processes may block functions such as neurotransmitter transport (60). 
 
3.2.2 Proteins trapped in aggregates: Intracellular aggregates of polyQ diseases are 
stained positive by antibodies to each specific disease protein or a certain fragment of it 
(53). They also show positive staining by antibodies against the expanded glutamine tract 
but not the normal range of glutamine residues (e.g. 1C2 antibody) (61). The fact that 
these aggregates stain positive for ubiquitin indicates that they contain ubiquitylated 
proteins (62). Polyglutamine aggregates also contain some proteasome subunits and 
molecular chaperones (29). Many transcription factors such as TBP and CBP were found 
to be localized in the aggregates which results from the interaction of these proteins with 
the expanded polyQ tract (32). Some proteins involved in apoptosis are found to be in the 
aggregates as well. For example, caspase 8 has been shown to be recruited into 
aggregates of HD patient postmortem brains (51). Entrapment of proteins into aggregates 
can be a temporary or permanent process. For example, in a HD cell model, molecular 
chaperones such as Hsp70 exhanges between the aggregates and soluble components of 
the cell, while TBP remains in the aggregates once it is recruited (63) . Clarifying what 
proteins are in the polyQ aggregates and why they are recruited is beneficial to 
understand the pathogenesis as well as to develop new therapeutics.  
 
3.2.3 Structure of polyQ aggregates: PolyQ-containing aggregates which can be seen 
under the light microscope are usually SDS-insoluble (53). The formation of the 
insoluble, amyloid-like fibril aggregates has been proposed as a nucleation-dependent 
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process (64). As shown in Figure 2A, an unstructured monomer transiently forms a β-
sheet structure. This β structured monomer acts a nucleation centre and soon recruits 
other monomers to form oligomers. Oligomer formation is the rate-limiting step of 
aggregation formation (64). Oligomers will finally form highly ordered β-sheet structured 
aggregates (64, 65). Biophysical analyses such as x-ray fiber diffraction studies, circular 
dichroism and computerized modeling have proposed several models for the β-structured 
monomer as shown in Figure 2B (64). For example, as shown in panel f, Perutz et al. 
proposed a β-helix structure of 20 Q residues per turn (54). This makes a total 40 Q 
residues which is a critical number for aggregation formation in vivo of polyQ diseases. 
This study also showed that Aβ, which makes of the extracellular tangle in AD and 
Sup35 (i.e. yeast prion protein) which makes prion aggregates, share same structural 
features with polyQ (54). Another recent study using a mutational analysis of the 
modified synthetic polyQ peptides suggested a structure shown in panel e. This model 
proposed that polyQ monomer forms a compact β-sheet structure with alternating 
elements of extended chain and turn (55).  
 
3.2.4 Roles of aggregates in toxicity: The most intriguing issue about polyQ aggregation 
regards the toxicity of these aggregates. Nuclear inclusions containing expanded polyQ 
proteins were thought to contribute to neuronal damage and degeneration in polyQ repeat 
diseases (53). For example, formation of aggregates precedes the symptoms in a HD 
mouse model (66). Reversal of aggregate formation also reverses the symptoms in a 
conditional HD mouse model (44). Bucciantini et al. showed that aggregation of two non-
disease-associated proteins is inherently highly cytotoxic (34). However results obtained  
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Figure 2A: PolyQ aggregation process  Adapted from (64, 65) 
PolyQ aggregation is proposed as a nucleation-dependent process (64). PolyQ-expanded 
proteins such as polyQ-expanded htt are not toxic when they present as monomer of 
random coiled structure. However, these monomers tend to have a conformation change 
to β-structured monomers (i.e. β-sheet, also see Figure 2B). These β-structured monomer 
then oligomerized into β-structured oligomers. Oligomerization is the rate limiting step of 
polyQ aggregate formation. Then, oligomers form the final insoluble aggregates. This 
step is fast. Whether the large insoluble polyQ aggregates trigger cell death is still the 
topic of much debate. β-structured monomers and oligomers may also be toxic although 
they do not form visible aggregates under light microscope (64, 65).  
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Figure 2B: Structure models of mutant polyQ monomer  
From Ross, C.A., Poirier, M.A., Wanker, E.E. and Amzel, M. (2003) Polyglutamine 
fibrillogenesis: the pathway unfolds. Proc Natl Acad Sci U S A, 100, 1-3. (64) 
Copyright (2003) National Academy of Sciences, U.S.A. 
 
Proposed models of PolyQ-expanded protein monomers: a. antiparallel poly-zipper; b. 
parallel poly-zipper; c. β-hairpin; d. compact random coil; e. compact β-sheet; f. β-helix 
(64). For detailed explanation of e and f, see text.  
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in a number of in vitro and in vivo models of polyQ repeat diseases have led to a re-
examination of the relationship between aggregates and toxicity (35, 58, 67-69). In 
transfected primary striatal neurons, accumulation of polyQ-expanded htt within nuclear 
aggregates was enhanced by agents such as BDNF and ciliary neurotrophic factor 
(CTNF), or expression of Bcl-XL, yet neuronal toxicity was reduced (35).  Furthermore, 
cotransfection of a dominant-negative ubiquitin-conjugating enzyme with polyQ-
expanded htt reduced aggregation but led to increased toxicity (35). In a transgenic mouse 
model of SCA-1, mutation of the self-association domain of polyQ-expanded ataxin-1 
blocked its aggregation, but did not affect its ability to cause degeneration of cerebellar 
Perkinje cells (58). One way to explain these controversies is that microscopic detectable 
large stable aggregates may not be toxic. The toxic forms might be intermediates such as 
β-sheet monomers and small oligomers (65). This issue will be further discussed in 
Chapter III. 
 
4. Molecular mechanisms underlying polyQ expanded protein induced neuronal 
toxicity  
 
4.1 Loss or gain of function: The presence of an expanded polyglutamine tract in each 
specific gene product may induce toxicity by a loss of its normal function or a gain of 
toxic function of the polyQ-expanded protein (70). Because most of these diseases are 
autosomal dominantly inherited diseases, the first studies to examine whether a loss of 
function plays a role in polyQ diseases came from genetic analysis. Does the number of 
copies of the gene affect the severity of the disease? This proves to be true for DRPLA 
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and SCA6 (71-74). For example, a homozygote SCA6 patient showed an earlier age of 
onset and more severe symptoms than his heterozygote sister who had the same CAG 
repeat length in the ataxin-6 gene (71). However, a similar phenomenon does not apply to 
HD. Heterozygote HD patients have no improvement in phenotype compared to 
homozygotes (70). This indicates at least a simple loss of normal huntingtin function is 
not enough to induce a neurodegenerative phenotype (70).  Therefore, a gain-of-function 
is thought to be the main cause of HD (70). 
 
A polyglutamine peptide itself is sufficient to induced toxicity in vitro and in vivo (70). 
For example, a GFP tagged with a CAG expansion has been used in many cell culture 
studies and shown to be toxic (51). An in vivo model showed that mouse bearing 
hypoxanthine phosphoribosyltransferase gene (Hprt), with an artificially introduced 
expanded polyglutamine tract cause neurological symptoms and early death (75). 
Therefore, a gain of function by the presence of polyQ can induce a neurodegenerative 
disease phenotype. However, the importance of a loss of normal protein function can not 
be evaluated at the present time, especially because the functions of most polyQ disease 
proteins are not known yet (70) . In DRPLA and SCA6, loss-of-function is certain to 
have an important physiological function (70-72). A detailed discussion concerning this 
issue in HD pathogenesis will be presented in the next section. 
 
4.2 Proteolysis: As mentioned earlier, several polyglutamine disease proteins including 
hungtintin, AR and ataxin 1 (38-40) were found to be more toxic when they are cleaved 
into a truncated form. Why are truncated forms more toxic and what enzymes are 
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involved in the proteolysis of full length proteins? It has been suggested that shorter 
forms of the protein more readily form oligomeric nuclei by relieving steric restrictions 
(76, 77). It is also reasonable to imagine that shorter forms of protein are easier to 
translocate into the nucleus (78, 79) and accumulate there to form nuclear aggregates. 
Several types of enzymes may be involved in the proteolysis of huntingtin, such as 
caspase 3/6 (49) and aspartic endopeptidases (80). In HD, the cleavage process is of 
particular interest because full-length htt protein is a large protein of 348 kD. The 
proteolysis process in HD and its importance will be discussed in the next section. 
 
4.3 Aspects of polyglutamine induced toxicity:  
 
4.3.1 Transcriptional activity: Because many transcription factors or cofactors contain 
short polyglutamine repeats or polyglutamine and proline-rich regions (81), several 
studies have examined whether their association with polyQ repeat proteins can impact 
gene transcription (32). For example, crucial transcriptional factors for neuronal survival 
such as TBP, Sp1, cofactor CBP have been found to interact with polyQ repeat proteins 
and, as a result, have their transcriptional regulatory activity reduced (46, 47, 82, 83). The 
reduction may be due to them being recruited into the aggregates such as CBP or 
interacting with a soluble form of polyQ protein such as Sp1 (46, 47). The main part of 
this thesis study focuses on the interference of CBP function in a HD cell culture model. 
Therefore, a very detailed introduction and discussion of this issue will follow in Chapter 
II. 
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4.3.2 Ubiquitin-proteasome degradation pathway (UPP): UPP is the main pathway for 
protein degradation and elimination of unwanted or toxic proteins in the cytoplasm (84). 
The UPP may attempt to degrade polyQ-proteins, but a failure to do so may result in 
polyQ aggregation. Several studies show that the presence of aggregates significantly 
inhibits UPP activity (33, 85). Some experiments addressed in chapter II of this 
dissertation study will provide new evidence concerning the effect on UPP and 
consequently UPP targeted protein by polyQ expanded htt.  
 
4.3.3 Molecular chaperones: Molecular chaperones may be functioning in at least two 
aspects of polyglutamine diseases. First, they may be involved in the folding of polyQ 
proteins. If the folding is not successful, this may lead to the misfolded protein 
accumulation (62). Polyglutamine containing protein may also cause a cellular stress that 
induces the expression of some molecular chaperones (62). It has been suggested that the 
imbalance between the limited chaperones activity and progressive build-up of toxic 
polyQ proteins leads to the onset of these diseases (65). Chapter III of this dissertation 
will describe experiments that address the roles of molecular chaperones in a cellular 
model of HD.  
 
4.3.4 Apoptosis: Morphological studies of the dying neurons in the polyglutamine 
diseases do not support clear apoptotic features. Electron microscopy (EM) examination 
of affected neurons in HD transgenic mice and patients’ brains show neither apoptosis 
nor necrosis characteristics (86). However, many in vitro and in vivo studies show that 
caspases activation plays an important role in polyQ induced cell death. Caspases are 
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activated by the overexpression of polyQ-expanded diseases proteins. For example, 
caspase 8 activation has been shown in a HD cell culture model (87) and even detected in 
HD patient postmortem brain (51). Caspase 1 activation is detected in a HD mouse model 
(50). In all these cases, inhibition of the activation of these caspases can prolong the 
survival and improve the symptoms of transgenic mice. Wild-type full-length huntingtin, 
may directly act on the inhibition of caspase activation (70). For example, it has been 
shown that normal htt prevents caspase-3 activity in striatal neurons (88). In addition, 
caspases may have other functions. For example, as previously mentioned in the 
proteolysis section, caspase 3 may be an enzyme that cleaves the full length htt into the 
truncated form (49).  
 
4.4 Selectivity of neuronal toxicity: Polyglutamine diseases proteins are expressed 
throughout the central nervous system. However, only certain subpopulations of neurons 
are affected (26). For example, in HD, only striatal and cortical neurons show 
pathological changes, although at every late stage other areas are also affected (89). In 
SCA1, only neurons in spinal cord and cerebellum are affected (57). Unfortunately there 
is no good explanation for selectivity so far. There are several possibilities. First, normal 
disease protein have specific function in the areas affected. For example, Htt has been 
shown to indirectly upregulate the transcription of BDNF in cortical neurons, which is an 
crucial neurotrophic factor released from cortex to the striatum (90). Therefore, striatal 
neurons are affected as a consequence of reduced BDNF expression in cortex. Second, 
each polyQ disease protein specifically interacts with other proteins such as apoptotic 
proteins and chaperones which may be enriched in the specific areas. The dysfunction of 
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these proteins may lead to specific toxicity (70). The third possibility, in HD or other 
polyQ diseases involving proteolysis of full length disease proteins, is that the proteolysis 
may be a cell-type specific process. A good example for this hypothesis comes from HD 
transgenic mouse model. Mouse bearing full-length polyQ-htt gene show selective 
neuronal toxicity in striatum, and truncated polyQ-htt is found in the striatum (91). 
However in other studies, transgenic mice bearing only N-terminal of htt with expanded 
CAG show toxicity in many areas of the brain with no selectivity (92). These results 
suggest that some proteins involved in the proteolytic process have specific expression 
pattern in the affected area in vivo. 
 
IV HUNTINGTON’S DISEASE (HD) 
 
1. Introduction:  
 
Huntington’s Disease is named for Dr. George Huntington, who first described this 
hereditary disorder in 1872 (26). 30,000 americans are affected by HD and another 
150,000 run the risk of developing the disease (26). This is much more than that the 
number of people affected by other polyglutamine diseases.  HD is also one of most well-
studied polyglutamine diseases. Research on HD has provided many insights into the 
common mechanisms underlying the pathogenesis of polyglutamine diseases. This 
dissertation work focuses on some of mechanisms of HD. Therefore, a detailed 
introduction on HD will be presented here. 
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The gene causing HD was discovered in 1993 (93). The mutation that causes the disease 
is an expansion of CAG triplet repeats with polymorphism within interesting 
transcription 15 (IT15) gene located on Chromosome 4p16.3 (93). The gene product of 
IT15 is named huntingtin (htt), which is composed of 3114 amino acids (26). The CAG 
repeat in the coding sequence encodes a polyglutamine repeat within the N-terminal 
domain of the protein. Normal individuals have 6-35 consecutive CAG repeats in their htt 
gene (42).  Expansion of htt from 36 to 41 glutamines is associated with an increased risk 
for the disease, whereas lengths of 42 and over invariably cause HD (42). HD is an 
autosomal dominantly inherited disease, with offspring of their affected parents having at 
least a 50% chance of inheriting the disease (26)  
 
HD patients normally start to show symptoms between the ages of 35-45. It is a 
progressive neurodegenerative disease. The average course of the disease is about 17 
years (89). Patients initially present with both cognitive dysfunction and motor 
disturbances such as chorea. They generally die from choking, infection or heart failure 
(89). The number of Q residues in the polyQ tract of htt in the patients is the most 
important factor in determining the severity of disease (70). Furthermore the age of 
symptom onset is inversely related to the number of CAG repeats in the huntingtin gene 
(38). For example, in juvenile cases of HD, the number of CAG repeat is sometimes 
beyond 100 (42). The severity of the symptoms is also positively related to the number of 
CAG repeats (70). 
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In normal individuals, the 348kD wild-type huntingtin protein is expressed throughout 
the body (94, 95). While htt has a higher expression in the brain, there is no evidence that 
it’s expression is further elevated in the striatal and cortical neurons which are the 
affected areas in HD patients (94, 95). The wild-type htt protein is a cytoplasmic protein 
in the adult nervous system (94, 95). The function of normal htt has not been firmly 
established yet. Some of the proposed functions of htt will be discussed in the 
“underlying mechanisms of HD” section.  
 
2. Pathology:  
 
2.1 Gross pathology and neuropathological classification: The earlier and most 
affected areas of HD are the striatum and cortex (89). In striatum, the medial 
paraventricular portions of the caudate nucleus (CN), the tail of the CN and the dorsal 
part of the putamen present the earliest neuronal loss (89). The striatal medium spiny 
GABAergic neurons, but not the glia cells are the targets of degeneration (89).  However, 
at very late stage of HD, degeneration affects most of the brain areas, rendering about 
95% of neuronal loss (89). Classically, the severity of the diseases is classified into 
grades 0-4 by Vonsattel et al. (89). Patients of Grade 0 are clinically diagnosed, but 
without microscopically neuronal loss in striatum. In patients of grade 1, caudate nucleus 
has a 50% of neuronal loss with moderate fibrillary astrocytosis. However there is no 
gross atrophy. From grade 2, gross atrophy of the striatum becomes more evident with 
more neuronal loss and astrocytosis. At grade 4, patients show extensive neuronal loss 
that is not only confined to the striatum. For example, caudate nucleus shows 95%  
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Figure 3: Striatum of HD patients at different disease stages 
 
From Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and 
Richardson, E.P., Jr. (1985) Neuropathological classification of Huntington's disease. J 
Neuropathol Exp Neurol, 44, 559-77. (89)  
Reproduced with permission from the Journal of Neuropathology and Experimental 
neurology. 
Striatum is the earliest and most affected areas in HD. A-D shows the atrophy of striatum 
including the caudate nucleus and the putamen regions of HD patient postmortem brains 
at different stages of the disease. A: Stage 0-1; B: Stage 2; C: Stage 3; D: Stage 4.  
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neuronal loss at stage 4. Other brain region such as hippocampus is severely affected as 
well.  Figure 3 shows the severity of atrophic striatum at CN and putamen in affected HD 
patients at different stages (89).  
 
2.2 Aggregates: As mentioned above, intracellular aggregation is the most important 
microscopical characteristic of the polyglutamine diseases including HD (53). An 
understanding of polyQ protein aggregation and its prevention is a critical step for 
therapeutic strategies. Aggregates were first detected in HD patients’ brain in 1997 by 
Difiglia et al. (38). In this study, some aggregates were stained positive with an antibody 
against the N-terminus of htt. These aggregates are detected both in the nucleus of striatal 
and cortical neurons (nuclear inclusion - NI) and within “dystrophic neurites”. Some of 
these aggregates are also ubiquitin-positive. The frequency of subcellular sites of 
aggregates is closely correlated with the onset of the disease and the number of CAG 
repeats. In juvenile patients who have more than 100 CAG repeat, nuclear aggregates are 
more frequently seen than those in neurites (38). As in HD patients’ brain, although 
polyQ-expanded htt shows expression throughout the brain, exhibiting the same pattern 
as wide type huntingtin (94, 95), aggregates are only confined to the striatum and cortex, 
the two most affected areas in HD even at late stages of the disease with brain atrophy in 
other areas(38, 96). However, the frequency of aggregates seen in cortex is higher than 
that seen in the striatum, although striatum is more affected than cortex (38).  
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3. Underlying mechanisms of HD pathogenesis: 
 
3.1 Loss or gain of function?  
The phenotypes of htt knockout mice models have been carefully reviewd by Cattaneo et 
al. (70). The mouse homologue of htt is called hdh. Mice that have both alleles of hdh 
knocked-out exhibit embryonic lethality before embryonic day 8.5, at the stage of 
gastrulation (97, 98). This result indicates that wild type hdh plays an important role in 
embryogenesis. However, heterozygote hdh knockout mice which only have a single 
copy of hdh gene appear to be normal without neurodegenerative symptoms (36, 97, 99). 
These results strongly support the idea that a gain-of-toxic-function by the polyQ 
expanded htt is the main cause of HD pathogenesis (70). Another study that supports this 
idea showed that a single copy of full-length hdh with an expanded CAG repeat can 
substitute for the wild-type hdh during embryonic neurogenesis (100). In contrast, in a 
conditional hdh knockout mouse model, inactivation of both alleles of hdh in adult mouse 
brain causes neurodegeneration (101) which strongly supports the idea that loss-of-
function may also play a role in the HD pathogenesis. Therefore, hdh-knockout models 
suggest a role for both an gain-of-function and loss-of-function of polyQ-expanded htt in 
HD (70).   
 
Do any human mutations implicate a pathological effect of htt loss of function? Wolf 
Hirschhorn Syndrome is a genetic disorder caused by a partial chromosomal deletion of 
the short arm from one copy of chromosome 4 (i.e. 4p16.3) (102), where the htt IT15 
gene is located . Patients with this syndrome show several growth retardation and mental 
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defects (102). The gene lost in the chromosomal region which is responsible for these 
symptoms is not known yet. However, these patients do not show symptoms of HD 
although one allele of IT 15 is deleted, suggesting that a loss-of-function of normal htt 
protein can not count for the pathogenesis for HD (103). As mentioned in the above 
section, heterozygotes patients with one allele of htt gene and an expanded CAG repeat 
do not show more severe symptoms and earlier onset than homozygote patients (70). This 
fact provides additional evidence to support that the hypothesis of a gain-of-toxic-
function of polyQ-expanded htt protein is crucial to induce neuronal toxicity.  
 
3.2 Loss-of-normal-function 
As mentioned above, wide type htt clearly plays a role in embryonic development. 
Normal htt is a cytoplasmic protein, but it has been found to be loosely associated with 
endoplasmic reticulum, microtubules, mitochondria and synaptic vesicles. This suggests 
that normal huntingtin may be involved in vesicle trafficking (104). Recently, it has been 
shown that wild type htt may have other functions that contribute to the selectivity and 
neuronal dysfunction of HD. Zuccato et al. showed that full-length wild type htt can 
indirectly upregulate the transcription of BDNF in cortical neurons, BDNF is a 
neurotrophic factor critical for the survival of striatal neurons (90). In contrast, the 
transcription of BDNF is reduced by the full-length htt with an expanded polyQ tract 
(90). Some other studies show that wild-type htt has anti-apoptotic function through 
caspase inhibition. It functions downstream of Bcl-2 and upstream of caspase 3. 
Truncated forms of htt without an expanded polyglutamines does not have such a 
function (88). Some in vivo evidence also support a role for wild type htt in apoptosis. In 
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a conditional mouse model generated by Dragatsis et al, double-knockout of hdh alleles 
in adult mouse shows apoptosis in cortical and striatal neurons (101). In addition, the 
function of htt interacting proteins may also provide clues about normal function of htt. 
For example, htt interacting proteins HAP1 (Huntingtin-associated protein1) and HIP1 
(Huntingtin-interacting protein 1) are also found to be associated with vesicles, 
supporting the role of normal htt in vesicle trafficking (70). HIP1, which interacts with 
wild type but not mutant htt, is a pro-apoptotic protein suggesting that normal htt blocks 
apoptosis through HIP inhibition (105). 
 
3.3 Gain-of-toxic-function: aggregates in the nucleus and neuronal processes 
Neurons expressing polyQ expanded htt exhibit neuronal aggregates, while those 
expressing only the normal range of Q residues never cause aggregates. The formation of 
aggregates is thought to bring new toxic functions to the affected neurons (53). 
Aggregation has been detected in numerous in vivo and in vitro systems including 
patients’ brain, transgenic mice’ brain, transgenic fly nervous system especially the 
photoreceptor neurons, primary neurons from mice and cell culture systems (38, 47, 48, 
66). PolyQ aggregates are found in the nucleus, the cytoplasm and neuronal processes – 
axon and dendrites (53). Therefore, aggregates may induce toxicity in the nucleus, 
cytosol and the neuronal processes. 
 
In the nucleus, the presence of aggregates interferes with gene transcription. PolyQ- 
expanded htt interacts with several crucial transcription factors and co-factors such as 
CBP, TBP and Sp1 and decrease their functions as transcriptional factors or cofactors. 
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Therefore the gene expression profile is significantly altered by polyQ-expanded htt 
(106). In the introduction of chapter II, the polyQ induced transcription deficiency will be 
carefully reviewed.  
 
Aggregates of polyQ expanded htt in both the nucleus and processes often show 
recruitment of ubiquitin, other components of UPP and molecular chaperones (65). It has 
been shown that aggregates inhibit the UPP, leading to insufficient degradation of other 
proteins (33). In the introduction of Chapter II, the dysfunction of UPP by polyQ-
expanded protein will be reviewed in detail.  
 
Aggregates of polyQ expanded htt may also cause degeneration of neuronal processes, 
especially axons (60, 91). By examining of amount and sites of aggregates in HD 
patients, the presence of aggregates containing the N-terminal htt in the axons has been 
suggested to induce the degeneration of the corticostriatal pathway in earlier stages of 
HD (60). Other studies showed that the degeneration of neuronal processes induced by 
aggregates occurs before any evidence of cell death seen from the nucleus (107, 108). 
These results emphasize the possibility of axonal dysfunction prior to the appearance of 
an obvious nuclear defect. The presence of aggregates in neuronal processes may block 
neurotransmitter transport or uptake by synaptic vesicles (91, 107). 
 
As aggregates are found to contain mostly truncated forms of htt with expanded 
polyglutamine, the proteolysis process of full length htt clearly is a critical step for the 
gain-of-toxic function of htt mutant phenotype in HD. Full-length htt with an expanded 
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polyglutamine tract is cleaved by certain proteases to form the truncated form, which then 
forms aggregates. In turn, the truncated and polyQ expanded htt may recruit wild type htt 
into the aggregates (70). The ability of certain subpopulation of neurons to cleave full-
length htt may provide some basis for selectivity of neurodegeneration (91, 109). The 
truncation process may also partially explain why HD patients do not show symptoms 
before disease onset although they carry the mutant htt gene from the very beginning. 
Transgenic mice with full-length mutant htt gene have a much later disease onset and 
longer life span than those with a truncated mutant htt gene (106). This is presumably 
because truncation is a progressive process. Once truncation is completed, the 
aggregation process is thought to begin. In vivo, both normal and HD patients show 
truncated htt fragment, either with a normal or an expanded polyQ repeats (110). 
Therefore, htt cleavage is a normal event. Importantly the short N terminal fragment of 
htt forms aggregates and induces toxicity only when it includes an expanded polyQ tract. 
 
The next question concerning the truncation process is what enzymes cleave htt. A few 
possibilities have been proposed. The first candidate is caspase 3. Full-length htt protein 
has several caspase 3 cleavage sites including the two active sites at amino acids 513 and 
552 (49). In cell culture models, mutation on the htt caspase cleavage sites reduced 
toxicity (49). The size of htt fragments resulting from caspase 3 cleavage seems to be 
much larger that those found in vivo (111). Other studies suggest that calpain, another 
class of proteases, may further cleave these large fragments into small ones (111). 
Another candidate is aspartic endopeptidases, which may cleave htt into different 
fragments in the nucleus and the cytosol. After this cleavage, htt fragments may be 
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processed by UPP, or if they are not degraded, form nuclear or cytoplasmic aggregates 
(80). Since full-length htt does not contain a putative nuclear localization signal (53), the 
truncation may also facilitate the nuclear translocation of polyQ expanded htt.  
 
3.4 Apoptosis 
Regardless of whether neuronal toxicity is induced by a gain or loss of function of htt, 
affected neurons receive many inputs of cell death such as oxidative stress, excitotoxity, 
mitochondrial dysfunction and loss of neurotrophins. Affected neurons appear to undergo 
cell death including apoptosis. As mentioned above, some evidence supports the view 
that apoptosis occurs in affected neurons of HD. Caspase 1, caspase 8, HIP are activated 
to induce toxicity in HD models (50, 51, 87, 105). Inhibition of caspase activation by 
inhibitors may improve the symptoms in HD transgenic mice and prolong their life span 
(50). In addition, proapoptotic signal transduction pathways, such as JNK pathway, have 
been reported to be activated by polyQ expanded htt (112). The significance of these 
studies is that the blockage of apoptosis may be a promising strategy for therapeutics. 
Figure 4 summarizes how both the gain and loss of function mutations within htt could 
finally lead to cell death in affected neurons.   
 
4. Therapeutics perspectives of HD 
 
The targets of HD therapeutics are very similar to those discussed in the 
neurodegenerative disease section. Here, I will just summarize what have been done in 
HD mice and patients. 
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Figure 4: Mechanisms of HD pathogenesis 
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Legends of Figure 4: PolyQ-expanded htt induced neuronal toxicity is a result of a 
combination of a loss-of-normal function of full-length wild type protein and a gain-of-
toxic-function of truncated protein with an expanded polyQ tract. Loss-of-function of 
wild type htt can lead to the downregulation of BDNF transcription and inteference of 
vesicle trafficking. Gain-of-toxicity can result in the recruitment of important cellular 
proteins into polyQ-htt containing aggregates such as transcritpional factors and 
components of the UPP. Both the loss and gain of functions can lead to disrupted 
neuronal functions in both the nucleus and in neurites, and finally result in neuronal 
death.  
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Although many reagents are effective in reducing polyQ induced toxicity in cell culture 
and lower organisms such as flies, various treatments on transgenic mice show only a 
limited improvement on symptoms and life span by 10-20 percent (113). Here are some 
examples: gutamate antagonists have been used to counter excitotoxicity (114).  Caspase 
inhibitors have been used to prevent apoptosis (50). Transglutaminase has been used to 
prevent aggregation (115), while congo red is used to reverse aggregation (45). In 
patients, some neuroprotective agents have been used in clinical trials (113). Riluzole and 
remacemide which are glutamate antagonists and coenzyme Q10 may have an effect on 
motor function improvement, but these minor effects do not appear to be statistically 
significant (113). Although there is still a long way for the final goal of curing HD, more 
and more drug targets are being identified based on exploring the mechanisms of polyQ 
induced neurodegeneration.  
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CHAPTER II 
DEGRADATION OF CREB-BINDING PROTEIN INDUCED BY 
POLYGLUTAMINE EXPANDED HUNTINGTIN 
 
I. INTRODUCTION 
 
1. Polyglutamine diseases and transcription deficiency 
 
There have generally been two ways to examine whether transcription is compromised in 
polyglutamine diseases (106). First researchers have assessed the function of specific 
transcriptional factors. The main reason is that a number of proteins regulating 
transcription contain a polyQ region (such as CBP), Q-rich region (such as Sp1) or 
proline-rich region (such as p53) (32). Interactions between Q residues may interrupt the 
normal function of the proteins, and could result in their recruitment into aggregates in 
polyQ diseases proteins (32). This is very reasonable hypothesis since even wild type 
proteins such as atrophin or full-length htt with a normal range of Q tracts can be 
sequestered into these aggregates (70). As discussed below (Table 4), a number of 
important transcriptional factors and cofactors are found to interact with polyQ disease 
proteins, leading to the disruption of their functions (106). 
 
Recent studies went on to look at gene transcription mainly by microarray analysis (106). 
A few microarray analyses have been done to look at the changes of mRNA levels in 
several polyglutamine diseases. These data reveal that some genes are similarly impacted 
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by polyQ in a context-independent manner (116). For example, SNFK1, a protein 
involved in histone phosphorylation has a consistent decreased level in transgenic mice of 
HD, DRPLA, SCA7 and SBMA, suggesting a potential role for histone regulation and 
gene transcription in polyQ diseases (116). Other genes that are consistently affected are 
those encoding neurotransmitter receptors, neurotransmitter and neuropeptides and signal 
transducing enzymes. (116). Many of the affected genes in polyQ disease microarray 
analysis contain binding sites within their promoters or enhancers for factors such as Sp1 
and CREB, which are known to be affected in polyQ disease models (106) (see below).  
 
1.1 Transcription factors affected by polyQ disease protein 
Table 4 lists some of the well-known transcriptional factors or cofactors that are affected 
by one or more polyglutamine diseases. They include transcriptional factors such as Sp1, 
coactivators such as CBP and TAFII130 and proteins in the basal transcriptional 
machinery such as TBP. Some of them such as CBP and TBP are recruited into the polyQ 
aggregates, indicating they interact with insoluble polyQ disease proteins (47). Some 
such as p53 and Sp1 are not recruited into the aggregates, indicating they interact with a 
relatively soluble fraction of polyQ expanded proteins, including “microaggregates” that 
are not detectable under the light microscope (46, 82). The putative interaction domains 
are mostly the polyQ, Q-rich or proline-rich regions of the transcription factors (32). 
Recently, proteins such CBP and pCAF have been suggested to interact with polyQ 
disease proteins via their histone acetyltranferase domains (HAT) (48). These interactions 
interfere with the transcriptional activation function of these proteins. Some of these 
transcriptional factors preferentially interact with the disease protein with an expanded 
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polyQ tract (32). These tighter interactions normally decrease their activity (32). As 
mentioned above, some of genes regulated by these factors are crucial for neuronal 
survival (106). 
  
Sp1 and CBP are the two most well-studied transcription factors that are affected in 
polyglutamine diseases. Here I will briefly discuss Sp1 as an example of how interference 
in the function of a transcriptional factor could cause toxicity in polyQ disease. In the 
next section, CBP will be particularly emphasized. Sp1 is a transcription factor that binds 
to the promoter DNA region of many genes such as dopamine D2 receptor (46). Sp1 
binds more tightly with polyQ expanded htt in vivo (i.e. patients) and in vitro (cell 
culture) (46). However, Sp1 is not recruited into the aggregates, indicating that it interacts 
with the soluble form of htt-polyQ (46, 117). In cell culture models, overexpression of 
Sp1 can rescue the toxicity induced by polyQ-expanded htt including a neurite extension 
defect (117). Sp1 dependent transcription is decreased by polyQ-expanded htt. This result 
is supported by the in vivo evidence that dopamine D2 receptor expression is 
significantly lowered in the striatum of HD patients at early stages of the disease (46, 
117).  
 
1.2 CREB-binding protein (CBP) and polyQ induced neuronal toxicity 
Effects of polyQ disease proteins on CBP, a transcriptional coactivator, have received 
considerable attention, given the established role for CBP and its target transcription 
factors (e.g. CREB) in neuronal cell survival (21). The major goal of this thesis is to 
elucidate the mechanism of the interruption of CBP function by polyQ-
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Table 4: Transcription factors and cofactors affected by polyglutamine diseases  Adapted from (32, 106) 
 
 Transcriptional 
factor 
Nuclear function polyQ 
diseases  
Interaction 
domain 
Differential 
binding 
with short 
or long 
CAG 
Recruitment 
into the 
aggregates 
Transcription 
affected 
Target 
genes that 
are affected 
Effect on 
polyQ 
induced 
toxicity 
         
CBP Transcriptional 
coactivator/HAT 
HD, 
DRPLA, 
SCA3, 
SBMA 
polyQ 
HAT 
more tightly 
with mutant 
Yes Yes Genes 
regulated by 
creb 
Yes 
p300 Transcriptional 
coactivator/HAT 
HD N/A N/A No Yes by 
decreasing 
HAT activity 
N/A N/A 
Sp1 Transcriptional 
factor 
HD C-terminus  more tightly 
with mutant 
No Yes Dopamine 
D2 receptor 
Yes 
TBP Basal 
transcriptional 
machinery 
HD, SCA3 polyQ  Yes N/A N/A N/A 
p53 Transcriptional 
factor 
HD N/A more tightly 
with mutant 
No Yes N/A N/A 
TAFII130 Transcriptional 
coactivator 
HD, SCA3 Q-rich NO Yes Yes CBP/SP1 
regulated 
genes 
Yes 
PQBP-1 Putative 
transcriptional 
corepressor 
SCA1 N/A Yes Yes Reduce Pol II 
phosphorylation
N/A Yes 
CtBP Transcriptional 
co-repressor 
HD N/A N/A N/A Yes N/A N/A 
p/CAF HAT HD HAT Yes N/A N/A N/A N/A 
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expanded htt. Therefore, I will provide a thorough introduction of CBP including its 
structure and functions. I will also review published data concerning how its function is 
interrupted in polyglutamine diseases.   
 
1.2.1 CBP (CREB-binding protein): structure and functions 
CBP is so named because it was first identified as the transcriptional coactivator for 
CREB. CBP, a large protein of 265kD, and its closely-related homolog p300 are 
transcriptional co-activators that can influence multiple functions including cell growth, 
proliferation, differentiation and apoptosis (118). As shown in Figure 5, CBP/p300 have 
interaction domains with hundreds of proteins (118).  
  
Although CBP can be divided into several domains, only some of them which are related 
to this study will be highlighted here.  For example, CBP interacts with CREB via the 
KIX CREB-binding domain, which also binds to other transcriptional factors (118). CBP 
binds with Mouse double minute 2 (Mdm2), a human E3 ubiqitin-ligase of UPP through 
the first Zinc finger domain. This interaction is important for degradation of p53 by 
Mdm2 (119). The HAT domain in the middle region of CBP carries its histone 
acetyltransferase activity (118). The glutamine/proline-rich (QP) domain near the C-
terminus associates with other coactivators including HAT proteins P/CIP and SRC-1 
(118).  Both N- and C-terminal regions of p300/CBP have transcription activation 
activity when they are fused to a heterologous DNA binding domain (120). In addition,  
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Figure 5: Functional domains of CBP/p300   Adapted from (118, 121) 
CBP/p300 have multiple functional domains with the ability to bind with numerous 
proteins. RID: Receptor binding domain. Q/P: Glutamine/Proline rich. BP-NLS: Biparate 
nuclear localization signal. See text for details.  
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there is a bipartite nuclear localization signal (NLS-BP) located in the middle region of 
CBP/p300 (118). CBP/p300 could implement their transcriptional coactivator activity by 
three different mechanisms as shown in Figure 6 (118). In one case, CBP/p300 acts as a 
bridge to connect certain transcriptional factors such as CREB with the basal 
transcriptional machinery (i.e. RNA polymerase II, TBP and other TAFs). In some cases, 
transcription of certain genes requires the coordination of multiple cofactors. Thus 
CBP/p300 could also act as a scaffold to recruit several other proteins including proteins 
with HAT activities. Finally the HAT activity of CBP/p300 could directly affect 
transcription (122, 123). HAT proteins are able to transfer an acetyl group to the ε-amino 
group of a lysine residue of the histone molecule. The acetylation level of chromatin-
associated histones plays a critical role in regulating transcription (118). High acetylation 
levels of histones represent an active transcription region of the chromatin. In contrast, 
low acetylation marks repression of transcription in that region (28). Therefore, proteins 
such as CBP/p300, SRC-1 and pCAF that have intrinsic HAT activities can directly 
activate transcription by remodeling chromatin structure. Histone deacetylases have 
opposite functions to that of HATs. The balance between these two types of enzymes 
plays an important role in transcription regulation. As a result, abnormal histone 
acetylation is involved in diverse human diseases including leukemia, solid tumors, and 
Rubinstein–Taybi Syndrome (RTS, (28). In addition to nucleosomal histones, CBP/p300 
can modify the acetylation level of other transcriptional factors as well in order to 
regulate their activities (120). 
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Figure 6: Models of CBP/p300 function as a transcription co-activator 
From Chan, H.M. and La Thangue, N.B. (2001) p300/CBP proteins: HATs for 
transcriptional bridges and scaffolds. J Cell Sci, 114, 2363-73 (118) Copyright of The 
Company of Biologists LTD, 2001 
CBP/p300 may function as a transcription co-activator by three distinct mechanisms: In 
model A, CBP/p300 act as a bridge to connect the basal transcriptional machinery with 
transcription factors such as CREB to activate gene transcription. In model B, when the 
transcription of certain genes required the coordination of transcription factors and 
multiple co-factors, CBP/p300 act as a scaffold to recruit all of these factors. In model C, 
CBP/p300 utilize their intrinsic HAT activity to acetylate chromatin and transcriptional 
factors to regulate transcription (118). Although this figure depicts the models for p300, 
similar mechanisms apply to CBP as well. 
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Based on the fact that CBP/p300 have numerous functions in a cell, it is very possible 
that their amount is limited (121). Mutations within a single copy of the CBP gene have 
been detected in RTS (124) and some types of acute leukemia (125). RTS is an 
autosomal-dominant disease with mental retardation, skeletal abnormalities and a high 
incidence of neoplasia (124). Most RTS patients are found to have only one normal CBP 
allele. In CBP knockout mice, homozygotes are embryonic lethal, while heterozygotes 
may be embryonic lethal or have other developmental deficiencies with some symptoms 
similar with RTS patients (126, 127). These in vivo results indicate that CBP levels are 
limiting under physiological circumstances and may be involved in multiple pathways 
(118).  
 
1.2.2 CBP and polyglutamine diseases: 
CBP is recruited into the polyQ aggregates in cultured cells, primary neurons, transgenic 
mice and postmortem brains of multiple polyglutamine diseases including HD, DRPLA, 
SBMA and SCA3 (47, 128). This suggests that the interruption of CBP function is a 
common mechanism underlying the pathogenesis of polyglutamine diseases.  
 
Nucifora et al. found that endogenous and transfected CBP are recruited into both nuclear 
and cytoplasmic aggregates of cultured cells expressing an htt construct with an expanded 
CAG repeat (Htt-N63-148Q). CBP is localized to the aggregates of HD patients’ brains 
as well. In rat primary cortical neurons, CBP effects on CREB are impaired, leading to 
reductions in CRE-dependent transcription and toxicity (47). The importance of this 
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reduction in CBP activity in expanded polyQ toxicity was revealed by experiments which 
showed a rescue of toxicity by CBP overexpression (47).  
 
What specific function of CBP is disrupted by this aberrant interaction and how can these 
findings lead to therapeutics of polyglutamine diseases? In another pioneering paper by 
Steffan et al., it was found that the HAT activities of CBP, p300 and pCAF are 
significantly reduced by polyQ expanded proteins as measured by acetyl-H4 and acetyl-
H3 levels. This leads to toxicity. Mostly importantly, in an htt-polyQ transgenic fly 
model, which showed degeneration in flies’ photoreceptor neurons, treatment with 
histone deacetylase inhibitors, which increases the acetylation level of chromatin, rescued 
polyQ induced toxicity (48).  
 
These two studies along with others show that the interruption of CBP function is critical 
in polyQ induced toxicity. In the two studies mentioned above, two domains of CBP are 
suggested to interact with polyQ-expanded huntingtin. The paper by Nucifora et al. 
emphasized the polyQ domain of CBP which localizes at the C-terminus (47). In this 
domain, CBP differs from most other transcriptional factors including p300 and Sp1 in 
that it contains a short polyglutamine repeat region. In human, there are 18 consecutive Q 
residues. In mouse, there are 15 (47). p300 and Sp1 only have Q-rich regions (47). In the 
paper, it was shown that a CBP mutant in which the polyQ region is deleted (CBP∆Q) 
was not recruited into the aggregates formed by htt-polyQ, and was not co-precipitated 
with htt-polyQ protein (47). The paper by Steffan et al. showed that the HAT domain of 
CBP and pCAF is the domain that interacts with the htt-polyQ (48). The region 
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containing the HAT activity of CBP is not exactly defined. It covers several domains, and 
may span from amino acid 1098 to 1758 of CBP (Figure 5) (120). In the study by Steffan 
et al, they used a GST pull down assay to assess the ability of different fragments of CBP 
to bind with polyQ (120). As shown in Figure 7, the fragment of amino acids 1459-1877 
of CBP has the strongest affinity with a htt exon1-51Q protein (48). The fragment covers 
part of HAT domain. In addition, for pCAF which is another HAT protein, its c-terminal 
region including the HAT was also co-immunoprecipitated with the htt-polyQ protein 
(48). In contrast, the C-terminal fragment of CBP which covers the polyQ domain did not 
show binding with htt-polyQ (48). They concluded that it is the HAT domain of CBP that 
interacts with polyQ expanded huntingtin. Therefore, htt-polyQ may interact with CBP 
through its polyQ domain or the HAT domain. 
   
2. Polyglutamine diseases and ubiquitin-proteasome pathway (UPP) 
 
Degradation of proteins in cells is mostly controlled by two pathways. The first is the 
vacuolar pathway such as through lysosomes, endosomes and endoplasmic reticulum. 
(84). For example, the lysosomes primarily degrade membrane proteins and extracellular 
components that are engulfed into the cell by endocytosis (62). The second is the 
ubiquitin-proteasome pathway (UPP). Although it was only identified 20 years ago, it has 
been found to be responsible for the degradation of most cellular proteins. Therefore, this 
pathway plays vital roles in numerous cellular processes (84). Caspases were identified as 
a way to partially degrade certain proteins. They cleave after aspartate residues of the  
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Figure 7: The HAT domain of CBP interacts with polyQ-expanded htt in vitro 
Adapted from (48) 
 
GST pull-down assays performed by Steffan et al. showed that amino acids 1459-1877 of 
CBP has the highest affinity for the htt exon1-51Q protein by GST pull-down assay (48). 
This fragment of CBP contains part of the HAT domain. In contrast, Nucifora et al. (47) 
found that the fragment containing the polyQ domain of CBP (amino acids 2181-2441) 
did not bind with the htt exon1-51Q protein in GST pull-down assay. 
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substrate (129). Caspases are mostly involved in signal transduction pathways that are 
crucial for apoptosis. As mentioned earlier, in the caspase cascade, caspases are cleaved 
by their upstream caspases and after activated cleavage downstream caspases or other 
targeting proteins. Similar to caspases, calpain-like proteases also function to cleave their 
substrates and partially degrade them (130). For example, calpains cleave lamin and other 
proteins which results in apoptotic morphology under certain circumstances (130). In 
addition, caspases and calpains may also function to cleave proteins outside the apoptotic 
signaling pathways. As mentioned earlier, both types of proteases may be able to cleave 
full-length htt protein into truncated and toxic fragments (111). 
 
2.1 Ubiquitin-Proteasome Pathway (UPP): process, components and general 
functions 
 
UPP contains multiple components and degrades targeted proteins in a multi-step 
manner. The whole process mainly involves two distinct stages, polyubiquitylation of the 
target protein, followed by its degradation by the proteases in the 26S proteasome (Figure 
8) 
  
 In order for a protein to be degraded by the UPP, it must be tagged with a special 
polypeptide called ubiquitin, which serves as a marker for the recognition of proteasome 
(84). Ubiquitin is a  polypeptide of 76 amino acids, which is well conserved in various 
species (84). Ubiquitin is attached to the protein for degradation by a covalent bond  
  56  
 
 
Figure 8: Schematic representation of ubiquitin proteasome pathway (UPP) for 
protein degradation  
  57  
Legends of Figure 8: The process of protein degradation via UPP involves the following 
steps:  
1) Ubiquitin molecules are activated by an E1 ubiquitin-activating enzyme; 
2) Activated ubiquitin molecules are transferred to an E3 ubiquitin ligase by an E2 
ubiquitin conjugation enzyme; 
3) E3 tranfers ubiquitin molecules to the protein substrate; 
4) Polyubiquitin chain formation is catalyzed by an E4 (ubiquitin chain assembly factor) 
along with E1 and E3 enzymes. 
5) The polyubiquitin chain serves as a tag for the protein substrate to be recognized by 
the 19S cap of the proteasome; 
6) The protein substrate is degraded by the 20S catalytic core of the proteasome to single 
amino acids;  
7) Ubiquitin moleculars are recycled.  
See text for details. 
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between an ε-NH2 group within an internal lysine residue of the protein. However, the 
preparation of this attachment requires another three enzymes, E1, E2 and E3 (84). At the 
very first step, ubiquitin must be activated by E1, ubiquitin-activating enzyme. Ubiquitin 
is activated to a high-energy thiolester on the glycine residue of its C-terminus by E1 
enzymes (84). After being activated, an E2, so called ubiquitin-carrier protein or 
ubiquitin conjugating enzyme, transfers the active ubiquitin to an E3 (84). E3 enzymes 
are called ubiquitin ligase, and bind either directly or indirectly to some specific proteins 
targeted for degradation (84). Therefore, the activated ubiquitin is attached to the protein 
which is recruited by E3. After the first ubiquitin molecule is attached to the protein, 
multiple ubiquitin molecules are added to the first ubiquitin on its own lysine 48. The 
step of polyubiquitin chain formation is catalyzed by E4 enzymes (ubiquitin chain 
assembly factor) along with E1 and E2 enzymes (131). The polyubiquitin chain serves as 
a marker for the recognition of 26S proteasome and subsequent degradation (84).  
 
There is only one human E1 gene, whose deletion is lethal (84). There are two isoforms 
of E1 that function either in the cytosol or the nucleus (84). There are more than a 
hundred E2s have been identified in mammalian cells. They define some specificity for 
the proteins that are being degraded (84). However, most of selectivity comes from E3 
enzymes. There are hundreds of E3s in mammalian cells. Each of them can only bind 
with one or a few proteins and target them to the proteasome (62). There are several 
families of E3s, such as E3α and E6-AP. Degradation of a protein by the proteasome may 
require ubiquitylation at more than one lysine residues, and ubiquitylation of a protein 
may not necessarily lead to degradation. Usually, the site of lysine residues for ubiquitin 
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attachment are different for purposes of degradation versus internalization and 
endocytosis (84).  
 
The 26S proteasome is composed of a 19S recognition cap and a 20S catalytic core. The 
19S recognition cap recognizes and binds the polyubiquitin chain and unfolds the protein 
before sending it to the catalytic core (132). The 20S core is composed of six catalytic 
sites, each of which also contains multiple subunits. They carry out three well-studied 
proteolytic functions including the trypsin-like, chymotrypsin-like and post-
glutamylpeptidylhydrolytic activities. All these enzymes work together to degrade 
proteins to small peptides (133), which are in turn rapidly hydrolyzed to amino acids by 
cytosolic peptidases (62). Proteasomal inhibitors can target the 20S catalytic core to 
inhibit the activity of UPP, therefore block general protein degradation. For example, 
compounds like lactacystin, MG132 and ALLN are widely used in research studies 
regarding the functions of UPP (33).  
 
Disruption of the UPP leads to a variety of diseases including cancers and 
neurodegenerative diseases.  The disruption can be caused by the loss-of function of a 
component of the UPP; or a mutation of a protein which leads to its insufficient 
degradation and excessive deposition. Accelerated degradation of certain protein targets 
of the UPP has also been found (84). Most frequently, in a disease state, more than one of 
these circumstances may occur simultaneously.  
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2.2 UPP and polyglutamine diseases 
As mentioned previously, the primary reason prompting researchers to study the roles of 
UPP in neurodegenerative diseases is that insoluble aggregates present in these diseases 
are usually ubiquitylated (62) (Table 2). Many types of proteins could be the targets for 
UPP degradation such as the proteins damaged by oxidants, incomplete proteins and free 
subunits of multmeric protein complexes (62). Of particular importance for 
polyglutamine diseases is misfolded proteins that are caused by polyQ mutations. An 
expanded polyglutamine tract within the disease proteins causes its aberrant folding 
which ultimately leads to its aggregation. The recruitment of ubiquitin and other 
proteasomal subunits (29, 62, 65) into polyQ containing aggregates indicates that UPP 
may be recruited in an initial effort to degrade these misfolded proteins. This is 
confirmed by other in vitro and in vivo assays. For example, treatment of proteasome 
inhibitors leads to more aggregates in both SCA1 and HD cell culture models (29). Both 
wild-type and mutant ataxin-1 can be ubiquitylated in vitro. However, the mutant can not 
be degraded by the proteasome as fast as that of the wild-type (29). Similar results were 
found in HD cell model as well (85). In a conditional HD transgenic mouse model, the 
reversal of aggregation leads to improvement of symptoms (44). However, the 
elimination of aggregates is dependent on the normal proteasome function, as lactacystin, 
a proteasomal inhibitor blocked aggregate clearance (134). Taken together, these data 
suggest that the polyglutamine expanded proteins undergo degradation through the UPP. 
However, despite of the effort of UPP, it is still unable to degrade the misfolded polyQ 
proteins adequately which finally leads to aggregation.  
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Recruitment of some of the components of UPP into the aggregates may deplete them 
and ultimately inhibit its normal ability to degrade other cellular proteins. This could 
contribute to cellular toxicity. Aggregation of polyQ-expanded proteins within cells has 
been found to reduce proteasomal function and contribute to toxicity (33, 85, 135). For 
example, Bence et al. showed that presence of either cystic fibrosis transmembrane 
conductance regulator (CFTR) or htt-polyQ aggregates impaired UPP activity in the cell, 
leading to insufficient degradation of a coexpressed unstable GFP construct (33). Another 
study shows that proteasomal function is increased in nuclear fraction of cells expressing 
htt-polyQ aggregates, while that of the cytoplasmic fraction is decreased (85). Overall, 
the presence of aggregates does influence normal UPP function which is harmful to the 
cells.  
 
In the majority of this thesis study, we used a hippocampal neuronal cell line (i.e. HT22 
cells) to examine the effects of polyQ-expanded htt on CBP localization and expression. 
As observed in other cell culture systems, the subcellular localization of expanded polyQ 
htt aggregates was an important determinant in its effects on HT22 cell toxicity. While 
these cells were useful in confirming the recruitment of endogenous CBP into expanded-
polyQ htt aggregates, they also revealed unique effects of htt on CBP accumulation. Loss 
of CBP function associated with polyQ-expanded htt resulted from either CBP 
recruitment into nuclear or large perinuclear inclusions or its degradation, and was shown 
to be directly related to toxicity as assessed in single cells by TUNEL assays. 
Furthermore, the selective enhancement of CBP ubiquitylation in HT22 cells expressing 
polyQ-expanded htt demonstrates that UPP may be mobilized to specific substrates when 
  62  
cells are challenged with disease-causing polyQ-expanded proteins. Some preliminary 
experiments were performed to examine mechanisms that may underlie the selectivity of 
CBP degradation.  
 
II MATERIAL AND METHODS 
 
1. Plasmids 
 
The htt (i.e. Htt-N63-19Q and Htt-N63-99Q) and CBP expression vectors (without Flag 
tag) used in these studies have been described previously (136). The HA-tagged ubiquitin 
plasmid (137) was obtained from Dirk Bohmann (University of Rochester). The full-
length Flag-CBP plasmid was obtained from Dr. Richard Goodman (Oregon Health 
Sciences University).  
 
Flag-CBP-∆Q was constructed from the full length Flag-CBP plasmid by the following 
procedures. The aim of this cloning is to substitute the 45 nucleotides (CAG/CAA) which 
encode 15 consecutive glutamine residues with an EcoRI site “GAATTC”. This polyQ 
domain is located at the C-terminus of CBP protein. Two PCR products were made 
before and after the “polyQ” site. The PCR product to the N-terminus is made from two 
primers: 5’CCAGCAGCAGATCCAGCATCGC3’ and 
5’CCGGAATTCGTGCTGTAGCAGCTGTCT3’ (underlined is the EcoRI site). The 
PCR product to the C-terminus is made from two primers: 
5’CCGGAATTCAATAGTGCCAGCTTGGCC3’ (underlined is the EcoRI site) and 
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5’CTCTAGCATTTAGGTGACACTA3’. The two PCR products were cut with SgrAI / 
EcoRI and EcoRI / NotI respectively. Then they were ligated with the large fragment 
digested from SgrAI / NotI of the original full-length Flag-CBP plasmid. Flag-CBP-∆Q 
was then sequenced to confirm the correct sequence.  
 
Flag-CBP-∆HAT was constructed from an in-frame deletion of the nucleotides encoding 
amino acids 1446-1866. To do this, the full length Flag-CBP vector was digested with 
BspE1/SgrAI. The large fragment from this digestion was ligated back itself to complete 
the construction of the Flag-CBP-∆HAT construct.  
 
2. Cell culture and transfection 
 
Mouse HT22 cells were maintained in Dulbecco's modified Eagle medium (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% FBS (Atlanta Biologicals, Norcross, GA, 
USA) and penicillin/streptomycin (BioWhittacker, Walkersville, MD, USA). Mouse 
neuroblastoma 2a (N2a) cells (American-type culture collection, ATCC), Manassas, VA, 
USA) were maintained in minimum essential medium Eagle (ATCC) supplemented with 
10% Vitacell FBS (ATCC) and penicillin/streptomycin. Cells were grown on coverslips 
in 6-well plates (Corning Incorporated Life Sciences, Acton, MA, USA) to 50% 
confluency at the time of transfection for IIF. For Western blot experiments, cells were 
growing on 60 mm plates. Transfections were performed using lipofectamine with cells 
maintained in serum free medium as recommended by the supplier (Invitrogen). 
Following 5 hours of exposure to the DNA–lipofectamine mixture, cells were refed with 
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medium containing 10% FBS. Following an additional 24–48 h incubation, cells were 
fixed and processed for indirect immunofluorescence (IIF). Lactacystin (Sigma 
Chemicals, St Louis, MO, USA), when used, was added 18 h after transfection to attain a 
final concentration of 5 µM. In this case, cells were harvested after additional 24 h 
incubation.  
 
3. Antibodies and IIF 
 
Cells grown on glass coverslips were fixed and permeabilized using 2% 
paraformaldehyde (Sigma) and 0.1% Triton X-100 (ICN Biomedicals, Costa Mesa, CA, 
USA) in PBS, pH 7.4 for 10 minutes. Fixed cells were incubated with primary antibodies 
diluted in PBS plus 10% goat serum at appropriate concentrations for 1–1.5 h at 37°C. 
The rabbit anti-c-myc A-14 antibody (Santa Cruz Biologicals, Santa Cruz, CA, USA) was 
used at a 1:200 dilution, the mouse anti-CBP C-1 antibody (Santa Cruz Biologicals) at 
1:50-1:100, mouse anti-Sp1 1C6 antibody (Santa Cruz Biologicals) at 1:50 and mouse 
anti-ubiquitin P4D1 antibody (Santa Cruz Biologicals) at 1:100. Following primary 
antibody incubation, cells were then washed and incubated with Rhodamine anti-rabbit 
IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) at 1:250 and FITC 
anti-mouse IgG (Chemicon International, Temecula, CA, USA) at 1:400, and 4',6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma) at 1:1000 for 1 h at 37°C 
before mounting. Coverslips were mounted onto slides using vectashield-mounting 
medium (Vector laboratories, Burlingame, CA, USA). IIF staining was examined using 
conventional fluorescence microscope. Approximately 100 transfected cells were counted 
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in each experiment. Data are presented as mean±SEM of at least three separate 
experiments with statistical analysis performed using Student's t-test.  
 
4. Western blot analysis and immunoprecipitation (IP) 
 
Protein extracts from transfected HT22 cells were prepared by lysis in buffer containing 
50 mM Tris–Cl (pH 7.5), 2 mM EDTA, 100 mM NaCl, 1% NP-40 and a protease 
inhibitor cocktail (1:1000) (Sigma). Following a 5 min centrifugation of the extract at 
14 000 g at 4°C, detergent-soluble supernatant and detergent-insoluble pellet fractions 
were collected. The insoluble fraction was solubilized with an equal volume of 2xSDS–
sample buffer (1x=62.5 mM Tris–HCl, pH 6.8, 10% glycerol, 20% β-mercaptoethanol, 
2% SDS) prior to loading onto gels while the soluble fraction was adjusted to a final 
concentration of 1x in SDS–sample buffer prior to loading. Unless specifically indicated, 
identical amounts of total protein were loaded per well. Western blot analysis was 
performed essentially as described previously (138). Primary antibodies used were the 
mouse anti-CBP C-1 antibody (Santa Cruz Biologicals) at 1:100 dilution, the BuGR2 
anti-GR monoclonal antibody (Affinity Bioreagents, Goldon, CO, USA) at 1:2000 
dilution, the mouse anti-c-Myc 9E10 antibody (Santa Cruz Biologicals) at 1:200 dilution, 
the mouse anti-flag antibody (Sigma) at 1:1000 dilution, the mouse anti-actin C-2 
antibody (Santa Cruz Biologicals) at 1:500 dilution, the mouse anti-Mdm2 SMP14 
antibody (Santa Cruz Biologicals) at 1:500 dilution, or the goat anti-lamin B M-20 
antibody (Santa Cruz Biologicals) at 1:100 dilutions. Western blots were developed using 
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an enhanced chemiluminescence detection system (Perkin Elmer Life Science, Boston, 
MA, USA).  
 
For IP experiments, HT22 cells were growing on 100mm plates. Cells were transfected 
with an htt vector (either 19Q or 99Q) and an HA-tagged ubiquitin vector at 1:1 ratio 
with total DNA amount of 18µg in each plate by lipofectamine. Cells were harvested 
approximately 48 hours after transfection. To obtain enough protein for IP, usually three 
identical 100mm plates of transfected cells were collected together as one sample. As 
described previously (139), cells were lysed using lysis buffer containing 50mM Tris-Cl 
(pH. 8.8), 5mM EDTA, 2% SDS, 10mM dithiothreitol, 100µM Sodium orthovanadate, 10 
mM sodium fluoride, 5mM N-Ethylmaleimide and proteasome inhibitors. Cell lysates 
were then diluted using dilution buffer containing 20 mM Tris-Cl, 150mM NaCl, 2mM 
EDTA, 100µM Sodium Orthovanadate, 10 mM sodium fluoride, 5mM N-Ethylmaleimide 
and proteasome inhibitors. Then the lysates were further homogenized by passing the 
extract through a 22-gauge needle three times to shear the DNA. The extract was 
centrifuged for 10 min at 14,000 × g at 4°C, and the resulting supernatant was incubated 
for at 4°C overnight with 20 µl of protein A/G-agarose (sc-2003; Santa Cruz 
Biotechnology, Inc.), which prior to this step, has been incubated with 5µl rabbit anti-
CBP A-22  antibody for each sample. Immunoprecipitates were washed three times by 
high salt washing buffer containing 20mM Tris-Cl, 500mM NaCl, 2mM EDTA, 2mM 
dithiothreitol, 10 mM sodium fluoride, 5mM N-Ethylmaleimide and proteasome 
inhibitors. After each wash, the mixture was centrifuged at top speed for 1-2 minutes to 
obtain the protein-antibody-agarose beads precipitates. The protein-antibody complex is 
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eluted in 1X SDS-Sample Buffer and following SDS-PAGE, subjected to Western blot 
analysis to detected HA-tagged ubiquitin using the HA antibody, or endogenous CBP or 
GR.  GR immunoprecipitation was performed using the CBP-depleted extracts in which a 
BuGR2 anti-GR monoclonal antibody was used. 
.  
5. Cell viability—TUNEL assay 
 
TUNEL staining was performed using an In Situ Cell Death Detection Kit, Fluorescein 
(Roche Molecular Biochemicals, Indianapolis, IN, USA). According to the 
manufacturer’s protocol, forty-eight hours after transfection, cells grown on coverslips 
were fixed using 4% paraformaldehyde in PBS at room temperature for 30 min. Cells 
were then washed and permeabilized with 0.1% Triton X-100 in PBS on ice for 2 min. 
Prior to TUNEL staining (1 h at 37°C under conditions recommended by the supplier), 
cells were incubated with a rabbit anti-c-myc antibody for 1–1.5 h at 37°C. At last, cells 
were incubated with a Rhodamine anti-rabbit antibody and DAPI as described in the IIF 
section. 
 
6. Cell viability—luciferase assay 
 
HT22 cells were transiently co-transfected with 0.05 µg of a pCMV-luciferase plasmid 
(140) and 1 µg of Htt-N63-19Q or 99Q plasmid in 35 mm tissue culture plates. Cells 
were harvested and lysed 48 h following transfection in Luciferase Cell Culture Lysis 
Buffer (Promega, Madison, WI, USA). 20 µl of supernatant collected after centrifugation 
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of the lysate were used to measure luciferase activity using the Luciferase Assay Reagent 
(Promega) as described previously (140). Relative light units were normalized in each 
sample to total protein concentration.  
 
III RESULTS 
 
1. Expression of polyQ-expanded htt in HT22 cells 
 
The mouse HT22 hippocampal neuronal cell line has provided a useful model of neuronal 
cell death and is particularly sensitive to oxidative stress (141-143). Since oxidative stress 
may contribute to the demise of vulnerable neurons in HD (144), we used HT22 cells for 
studies of toxicity upon expression of transfected polyQ-expanded htt. HT22 cells were 
therefore transfected with truncated htt protein that contains 63 N-terminal amino acids 
and either 99 (Htt-N63-99Q) or 19 (Htt-N63-19Q) consecutive glutamine residues. Figure 
9 shows the schematic diagrams of the two constructs used. Htt-N63-99Q, but not Htt-
N63-19Q, protein expressed in a variety of transfected neuronal and non-neuronal cell 
lines forms aggregates and induces toxicity (136). As will be shown below, this 
dependence on polyQ repeat length for aggregate formation and toxicity (136, 145) is 
also observed in HT22 cells (Figures 10 and 11). Note that both constructs encode 
truncated htt proteins, as Htt-full-length-99Q protein showed neither aggregates nor 
toxicity in transfected N2a cells (136). When Htt-N63-99Q protein was visualized in 
transfected HT22 cells by IIF four distinct staining patterns were observed (Figure 10). 
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Figure 9: Schematic representation of Htt-N63-19Q/99Q constructs 
Construct 1 (Htt-N63-19Q) encodes an N-terminal truncated form of huntingtin protein 
which contains the N-terminal 63 amino acids, a 19Q tract within the 63 amino acids and 
a c-myc epitope at its C-terminus.  Construct 2 (Htt-N63-99Q) encodes the same protein 
as construct 1, except that it contains a 99Q tract within the protein in place of the 19Q 
tract. 
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Figure 10: Expression of Htt-N63-19/99Q in HT22 cells 
 Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red and by DAPI to reveal nuclei in blue. Overlap of Htt-N63-99Q 
with nuclei is shown in each panel. Panel A shows that Htt-N63-19Q is expressed in cells 
as diffused cytoplasmic staining. Panels B–E show the expression patterns of Htt-N63-
99Q. Htt-N63-99Q may be expressed in a cell as diffused cytoplasmic staining (B), 
nuclear aggregates (C), cytoplasmic aggregates (D) or perinuclear aggregates (E). 
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In the majority of HT22 cells (typically 35–40%) Htt-N63-99Q was found in large 
nuclear aggregates (Figure 10C), while cytoplasmic aggregates (Figure 10D), diffuse 
cytoplasmic staining (Figure 10B) and large perinuclear aggregates were also observed 
(Figure 10E). Perinuclear aggregates have been observed previously in 293 cells 
expressing mutant htt protein (135) and are defined by their localization, size (i.e. larger 
than nucleoli), and their association with distorted nuclear morphology. These diverse 
staining patterns of a polyQ-expanded protein are not unique to HT22 cells and have been 
observed in many other transfected cell lines (136, 145). 
 
Numerous methods have been used to examine the cellular toxicity induced by polyQ 
expanded proteins such as TUNEL, propidium iodide (PI) and tryphan blue staining (42). 
To more precisely quantify cell death in transfected cell populations, some methods have 
been applied that rely on the reduction in protein levels or activity (e.g. GFP (47), firefly 
luciferase (146)) expressed from cotransfected plasmids. To verify that polyQ-expanded 
htt is indeed inducing cell death in HT22 cells, cells were cotransfected with a luciferase 
reporter plasmid and Htt-N63-19Q or Htt-N63-99Q expression plasmids. The principle of 
using luciferase assay to test toxicity is based on the fact that the degradation of 
luciferase is accelerated in dying cells (146). As shown in Figure 11, luciferase activity in 
HT22 cells expressing Htt-N63-99Q was only 10% of that recovered in cells expressing 
Htt-N63-19Q, indicating 99Q expression cells exhibit significant toxicity comparing to 
19Q.  Luciferase assay has also been applied in another study to demonstrate the polyQ- 
expanded huntingtin induced toxicity (45). Therefore, in HT22 cells Htt-N63-99Q protein  
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Figure 11: Cell death induced by Htt-N63-99Q  
Viability of HT22 cells was assessed by measuring luciferase activity derived from a 
CMV-luciferase reporter plasmid co-transfected (at a 1:20 ratio) with either Htt-N63-19Q 
or Htt-N63-99Q plasmids. Data shown are average (±SEM) of four independent 
experiments (*P<0.05). 
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shows both the aggregation feature and cellular toxicity, indicating it is a valid in vitro 
system to study HD.  
 
2. Distinct responses of CBP to polyQ-expanded htt in HT22 cells 
 
As mentioned in the Introduction, various transcription factors and cofactors are recruited 
into aggregates containing polyQ-expanded protein (47, 63, 82, 128). Recruitment of the 
CBP transcriptional coactivator into polyQ repeat protein aggregates appears to play an 
important role in in vitro toxicity and is a characteristic of vulnerable brain tissue in HD 
and mouse models of the disease (47). CBP is a nuclear protein that exhibits diffused 
nuclear staining in the cell. We used a mouse anti-CBP antibody to examine endogenous 
expression of CBP. The specificity of the antibody in IIF assay is shown in Figure 12. In 
HT22 cells that are transfected with Htt-N63-99Q, endogenous CBP is recruited into 
nuclear aggregates containing Htt-N63-99Q protein (Fig. 13 A–D). Endogenous CBP is 
also recruited into perinuclear Htt-N63-99Q protein aggregates (Fig.14 E–H). In cells 
expressing aggregated cytoplasmic Htt-N63-99Q protein, endogenous CBP exhibits a 
uniform diffuse nuclear staining pattern (Fig. 14 A–D). This apparently normal nuclear 
staining pattern of CBP is observed in all cells expressing cytoplasmic Htt-N63-99Q 
protein that is not visibly aggregated (data not shown). In non-transfected HT22 cells or 
transfected cells expressing Htt-N63-19Q, CBP also shows diffuse nuclear staining (data 
not shown). Surprisingly, in addition to the recruitment of endogenous CBP into 
expanded polyQ htt protein aggregates, we noticed many cells where CBP staining was 
diminished (Fig. 13 E–H). As summarized in Figure 15, in 55% of HT22 cells  
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Figure 12: Specificity of CBP antibody  
HT22 cells were stained with a mouse anti-CBP antibody to reveal endogenous CBP in 
green, as shown in C. To examine the specificity of this antibody, HT22 cells were 
stained without primary antibody as shown in A. Cells were also stained with anti-CBP 
antibody which was previously incubated with corresponding blocking peptide at 1:50 
ratio, as shown in B. The same dilution of FITC anti-mouse secondary antibody was used 
in all the experiments. Nuclei were co-stained blue by DAPI as shown in D to F. 
Preincubation of CBP antibody with the blocking peptide blocked the diffused nuclear 
staining pattern of CBP in HT22 cells (comparing B with C).  
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Figure 13: Localization and expression of endogenous CBP in HT22 cells containing 
Htt-N63-99Q nuclear aggregates  
Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red (A, E) and a mouse anti-CBP antibody to reveal endogenous 
CBP in green (B, F). Areas of overlap between CBP and Htt-N63-99Q are shown in 
yellow (C, G). Htt-N63-99Q overlap with nuclei stained blue by DAPI is shown in D and 
H. Panels A–D show recruitment of endogenous CBP into Htt-N63-99Q nuclear 
aggregates. Panels E–H illustrate the loss of endogenous CBP that is observed in some 
(i.e. 55%) HT22 cells expressing Htt-N63-99Q nuclear aggregates. 
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Figure 14: Localization of endogenous CBP in HT22 cells containing Htt-N63-99Q 
within cytoplasmic and large perinuclear aggregates  
Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red (A, E) and with a mouse anti-CBP antibody to reveal endogenous 
CBP in green (B, F). Areas of overlap between CBP and Htt-N63-99Q are shown in 
yellow (C, G). Htt-N63-99Q overlap with nuclei stained blue by DAPI is shown in D and 
H. Panels A–D show that endogenous CBP maintains normal diffuse nuclear staining in a 
cell containing Htt-N63-99Q cytoplasmic aggregates. In H, the upper cell contains a 
perinuclear Htt-N63-99Q aggregate that ‘pushes’ and deforms the adjacent nucleus. CBP 
is recruited into the Htt-N63-99Q perinuclear aggregate (F). 
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Figure 15: Quantitative analysis of endogenous CBP expression in HT22 cells 
containing Htt-N63-99Q aggregates. 
Data shown are average of four independent experiments. Approximately 100 cells 
containing Htt-N63-99Q aggregates were counted in each experiment. In 95% of HT22 
cells containing Htt-N63-99Qnuclear aggregates, CBP is no longer homogeneously 
distributed throughout the nucleus but either recruited into aggregates (40%) or no longer 
visible (55%). In contrast, CBP maintains its normal diffuse nuclear staining in cells 
containing cytoplasmic Htt-N63-99Q aggregates. 
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expressing nuclear aggregates of Htt-N63-99Q, CBP staining was undetected. 
Endogenous CBP staining was also dramatically reduced in 40% of transfected HT22 
cells containing perinuclear Htt-N63-99Q protein aggregates. Under our IIF conditions, 
CBP was detected in 98% of HT22 cells expressing diffuse cytoplasmic Htt-N63-99Q 
protein, non-transfected cells or those expressing Htt-N63-19Q protein (data not shown). 
The apparent loss of endogenous CBP was also observed in 30% of transiently 
transfected N2a neuroblastoma cells expressing Htt-N63-99Q (data not shown) and thus 
is not a property unique to HT22 cells.  
  
In order to test the selectivity of Htt-N63-99Q induced effects on CBP, we examined the 
localization of endogenous Sp1 transcription factor in transfected HT22 cells. Previous 
studies in N2a cells showed that the diffuse nuclear localization of Sp1 is maintained in 
transfected cells expressing polyQ expanded htt protein (47). As shown in Figure 16 A–
H, the diffuse nuclear staining pattern of Sp1 in HT22 cells is not altered upon expression 
of Htt-N63-99Q protein, irrespective of the localization of htt protein. There is no 
evidence of loss of Sp1 staining even in cells with a very condensed nucleus (data not 
shown). We also examined the localization of ubiquitin and the HDJ-2 molecular 
chaperone in Htt-N63-99Q transfected HT22 cells. As expected from previous studies in 
other cell lines and tissues (29, 147-149), both ubiquitin (Figure 17 A–H) and HDJ-2 
(data not shown) were recruited into Htt-N63-99Q nuclear aggregates. Thus, the apparent 
loss of CBP that results from expression of polyQ-expanded htt within nuclear or 
perinuclear aggregates is selective and not characteristic of either another htt-interacting  
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Figure 16: Localization of endogenous Sp1 in HT22 cells containing Htt-N63-99Q 
nuclear or cytoplasmic aggregates  
Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red (A, E) and a mouse anti-SP1 antibody to reveal endogenous SP1 
in green (B, F). Areas of overlap between SP1 and Htt-N63-99Q are shown in yellow (C, 
G). Htt-N63-99Q overlap with nuclei stained blue by DAPI is shown in D and H. Panels 
A–D show that endogenous SP1 maintains its normal diffuse nuclear staining pattern in 
cells containing Htt-N63-99Q nuclear aggregates. Panels E–H show that endogenous SP1 
maintains its normal diffuse nuclear staining in cells containing cytoplasmic Htt-N63-
99Q aggregates. 
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Figure 17: Localization of ubiquitin in HT22 cells containing Htt-N63-99Q nuclear 
or cytoplasm aggregates  
Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red (A, E) and with a mouse anti-ubiquitin antibody to reveal 
endogenous ubiquitin in green (B, F). Areas of overlap between ubiquitin and Htt-N63-
99Q are shown in yellow (C, G). Htt-N63-99Q overlap with nuclei stained blue by DAPI 
is shown in D and H. Panels A–D show that ubiquitin is recruited into Htt-N63-99Q 
nuclear aggregates. Panels E–H show that some ubiquitin is recruited into cytoplasmic 
Htt-N63-99Q aggregates, although the majority of ubiquitin remains within the nucleus.
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transcription factor (i.e. Sp1) (46, 117), or other proteins recruited into polyQ-expanded 
htt aggregates.  
 
Although these preliminary results are partially similar with other published work, such 
as the recruitment of CBP into aggregates of polyQ-expanded htt, several points drew our 
attention for further analysis. For example, we found that CBP expression is affected only 
by the nuclear or perinuclear aggregates, but not the cytoplasmic aggregates (Figures 13 
to 15). In the paper by Nucifora et al, they found that in most cells which showed 
cytoplasmic aggregates, transfected CBP was entirely recruited into cytoplasmic 
aggregates as well (47). The advantage of our study is that we examine the expression of 
endogenous CBP, and therefore may provide data that is biologically more relevant. This 
differential effect on CBP by the localization of aggregates prompted us to study the 
correlation between CBP defect and nuclear toxicity, as shown below.  
 
3. HT22 cell toxicity is associated with the formation of nuclear aggregates 
containing polyQ-expanded htt 
 
The loss of CBP function has been found to be a major factor in the cell death induced by 
polyQ-expanded proteins (47, 82, 106). In HT22 cells, the subcellular localization of Htt-
N63-99Q has an impact on CBP recruitment or degradation (see above). In order to 
examine whether CBP localization has an impact on Htt-N63-99Q induced toxicity, we 
used a TUNEL assay to stain transfected HT22 cells. As show in Figure 18 and 
summarized in Figure 19, 80% of transfected HT22 cells expressing Htt-N63-99Q  
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Figure 18: Toxicity in HT22 cells expressing Htt-N63-99Q aggregates 
Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red (A, E) and with a TUNEL assay kit to detect DNA damage in 
green (B, F). Areas of overlap between CBP and Htt-N63-99Q are shown in yellow (C). 
Htt-N63-99Q overlap with nuclei stained blue by DAPI is shown in D and H. HT22 cells 
expressing nuclear Htt-N63-99Q aggregates are positive in TUNEL assay (C) while cells 
containing cytoplasmic Htt-N63-99Q aggregates are negative in TUNEL assay (G). 
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Figure 19: Quantitative analysis of cell death by TUNEL assay in HT22 cells 
expressing Htt-N63-99Q aggregates. 
Data are from the average of four independent experiments. Approximately 100 cells 
containing Htt-N63-99Q aggregates were counted from randomly selected fields in each 
experiment. 
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nuclear aggregates were TUNEL-positive, while only 20% of the cells containing 
cytoplasmic aggregates of Htt-N63-99Q were TUNEL-positive. These results are 
consistent with other published studies examining polyQ-expanded htt in transfected cells 
where the extent of cellular toxicity was correlated with nuclear localization of polyQ-
expanded htt (78, 150). However, our results are unique in demonstrating at a single cell 
level a relationship between the loss of CBP function and cell toxicity. Therefore, along 
with the luciferase assay (Figure 11), two independent assessments of cell death reveal 
Htt-N63-99Q-induced toxicity in HT22 cells, either at the level of individual cells 
(Figure 18 and 19) or transfected cell populations. 
  
4. PolyQ-expanded htt selectively enhances CBP engagement with the UPP 
 
Another interesting point is that we detected a loss of CBP staining is some cells 
containing nuclear or perinuclear aggregates. We asked the question whether this loss of 
CBP reflects its enhanced degradation. Given the important role of UPP in polyglutamine 
diseases, we suspected that the loss of CBP staining may be related to the altered UPP 
function in the presence of Htt-N63-99Q. 
 
Despite the variability in both Htt-N63-99Q localization and the response of CBP (Figure 
15), we were able to detect a reduction in transfected CBP levels by Western blot analysis 
of HT22 cell populations expressing Htt-N63-99Q but not Htt-N63-19Q (Figure 20). 
Note that the decreased CBP level can be explained in at least three ways. A few 
previously published papers suggest that loss of CBP as the result of recruitment of CBP  
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Figure 20: Reduction of soluble CBP levels in HT22 cells expressing Htt-N63-99Q 
Soluble protein extracts were prepared from HT22 cells transfected with a CBP 
expression plasmid, Htt-N63-99Q or Htt-N63-19Q expression plasmids, and then 
subjected to Western blot analysis to detect CBP (top panel). Stripped blots were probed 
with an anti-lamin B (bottom panel) antibody to provide an internal control for protein 
loading. Blot shown is representative of three separate transfection experiments where 
reductions in CBP levels (normalized to lamin B expression) in Htt-N63-99Q expressing 
cells, relative to those expressing Htt-N63-19Q, varied from 40 to 60%.
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into insoluble aggregates, which therefore reduces the levels of soluble level of CBP (47). 
We are unable to detect any CBP in the insoluble fraction of the cell lysates, in which 
insoluble Htt-N63-99Q can be detected and do not favor this interpretation (see later 
Figure 24). Alteratively CBP expression may be inhibited at the transcription level. This 
appears to be unlikely since the level of CBP mRNA may be slightly increased when 
coexpressed with a polyQ-expanded htt protein (128). Therefore, in our HT22 cell 
system, the Western blot data support the IIF analysis, suggesting that selective CBP loss 
detected within individual cells is due to its enhanced degradation. 
  
Since CBP may be a substrate for proteasome-mediated degradation (151), we examined 
whether proteasome inhibition would reduce CBP loss observed in some HT22 cells 
expressing nuclear Htt-N63-99Q. Effects of proteasome inhibitors on the loss of CBP in 
cells expressing polyQ-expanded htt might also rule out CBP synthesis as a target of 
mutant htt. As shown in Figure 21 and quantified in Figure 22, treatment of HT22 cells 
with the irreversible proteasome inhibitor, lactacystin, significantly reduced the fraction 
of cells that exhibited reduced CBP expression. In this particular experiment, 40% of cells 
expressing nuclear aggregates of Htt-N63-99Q exhibited CBP loss in the absence of 
lactacystin treatment (Figure 22). Since the percentage of cells with nuclear aggregates of 
Htt-N63-99Q was not affected by lactacystin, the decrease in cells showing CBP loss is 
accompanied by an increase in cells exhibiting diffuse nuclear staining of CBP 
(Figure 22). These results are compatible with previous studies (135) showing lactacystin 
effects on polyQ-expanded htt aggregation, since lactacystin treatment did affect Htt-
N63-99Q nuclear aggregation, leading to an increase in the fraction of cells containing  
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Figure 21: Lactacystin reduces endogenous CBP loss in HT22 cells expressing Htt-
N63-99Q nuclear aggregates  
Transfected HT22 cells were co-stained with a rabbit anti-c-myc antibody to reveal Htt-
N63-99Q protein in red (A) and with a mouse anti-CBP antibody to reveal endogenous 
CBP in green (B). Areas of overlap between CBP and Htt-N63-99Q are shown in yellow 
(C). Htt-N63-99Q overlap with nuclei stained blue by DAPI is shown in D. Endogenous 
CBP maintains its normal diffuse nuclear staining in cells expressing Htt-N63-99Q 
nuclear aggregates upon treatment of cells with lactacystin, a proteasome inhibitor. 
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Figure 22: Quantitative analysis of lactacystin effects on endogenous CBP 
localization in HT22 cells containing Htt-N63-99Q nuclear aggregates  
Data are from the average of three independent experiments. Approximately 50 cells 
containing Htt-N63-99Q nuclear aggregates were counted from randomly selected fields 
in each experiment. Approximately 35% of cells containing nuclear aggregates show 
homogeneous CBP staining (i.e. open bars) upon the addition of lactacystin compared to 
5% of such cells not treated with lactacystin (*P<0.05). In addition, the amount of HT22 
cells exhibiting CBP loss (i.e. gray-filled bars) is reduced from 40 to 20% upon addition 
of lactacystin (*P<0.05).  
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Figure 23: Quantitative analysis of aggregate formation in lactacystin-treated HT22 
cells containing Htt-N63-99Q nuclear aggregates  
Data are from the average of three independent experiments. Approximately 50 cells 
containing Htt-N63-99Q nuclear aggregates were counted from randomly selected fields 
in each experiment. 
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Figure 24: Lactacystin treatment reduces solubility of Htt-N63-99Q in HT22 cells 
Detergent-soluble and -insoluble fractions were prepared from either untreated or 
lactacystin-treated (5 µM, treated 18 h after transfection for 24 h) HT22 cells transfected 
with an Htt-N63-99Q expression plasmid. Equivalent amounts of total soluble protein 
and cell equivalents of insoluble protein were separated by SDS–PAGE and subjected to 
Western blot analysis to detect Htt-N63-99Q protein. Insoluble Htt-N63-99Q protein was 
detected in the stacking gel. This blot is representative of three separate transfection 
experiments. The expression level of Htt-N63-19Q protein was not changed by 
lactacystin treatment (data not shown). 
 
  
 
Figure 25: Induction of Hsp70 by lactacystin in HT22 Cells 
HT22 cells growing on 60mm plates were treated with lactacystin of 10µmol (lane 2) or 5 
µmole (lane 3) or ddH2O (lane 1) for 18 hours. Cells were then collected and Hsp70 
levels were detected by Western blot analysis. Consistent with other published data, 
Lactacystin treatment leads to activation of Hsp70.  
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multiple (i.e. >3) nuclear aggregates (Figure 23). This increase in Htt-N63-99Q 
aggregation by lactacystin treatment was also revealed by Western blot analysis, which 
also showed a corresponding reduction in soluble Htt-N63-99Q (Figure 24 left) 
accompanied with more 99Q protein in the insoluble fraction (Figure 24 right).  The 
effectiveness of lactacystin in altering proteasome function was also confirmed by the 
induction of heat shock protein 70 (Hsp70) in lactacystin-treated HT22 cells (Figure 25). 
Hsp70 induction is a hallmark of proteasome inhibition in a number of cell types (152). 
  
The recovery of CBP expression upon lactacystin treatment of HT22 cells expressing 
nuclear Htt-N63-99Q suggests that CBP recruitment to the UPP may be enhanced as a 
consequence of polyQ-expanded htt expression. Since proteasome targeting requires 
ubiquitin modification, we examined whether increased CBP ubiquitylation accompanied 
Htt-N63-99Q expression. Endogenous CBP ubiquitylation was assessed using IP from 
extracts prepared following co-transfection of HT22 cells with HA-tagged ubiquitin and 
Htt-N63 plasmids. Gels used for this Western blot analysis were loaded to attain 
equivalent amounts of total CBP levels/lane (Figure 26A, top panel) in order to aid in 
comparison of CBP ubiquitylation. As shown in Figure 26A (bottom panel), endogenous 
CBP ubiquitylation was enhanced in HT22 cells expressing Htt-N63-99Q, but not Htt-
N63-19Q protein. Importantly, detection of ubiquitylated CBP in Htt-N63-99Q 
transfected cells did not require the pharmacological inhibition of proteasome function, 
which on its own leads to increased accumulation of ubiquitylated CBP (Fig. 26A, bottom 
panel). In the absence of htt proteins, lactacystin treatment is able to induce ubiquitylation  
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Figure 26: Selective enhancement of endogenous CBP ubiquitylation in Htt-N63-
99Q expressing HT22 cells 
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Legends for Figure 26: HT22 cells were transfected and an HA-tagged ubiquitin 
expression plasmid and either Htt-N63-19Q or Htt-N63-99Q expression plasmids. Where 
indicated, 5 µM lactacystin was added to transfected cultures for 24 h. Soluble extracts 
from transfected cells were subjected sequentially to an immunoprecipitations with first, 
an anti-CBP antibody (A) and then an anti-GR (B) antibody. Immunoprecipitated 
proteins were subjected to Western blot analysis to detected HA-tagged ubiquitylated 
proteins (A and B), or endogenous CBP (A) or GR (B) in the identical samples on 
parallel blots. 
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of endogenous CBP in HT22 cells, indicating that CBP may be degraded through UPP 
under normal conditions. In order to reveal whether Htt-N63-99Q effects on CBP were 
selective, we examined glucocorticoid receptor (GR) ubiquitylation in the same extracts 
used for analysis of CBP ubiquitylation. GR is a substrate for the UPP in HT22 cells, as 
revealed by the increased accumulation of ubiquitylated receptor upon lactacystin 
treatment (Figure. 26B). This corroborates previously published work from our laboratory 
where proteasome inhibition by MG132 treatment of HT22 cells was found to increase 
GR ubiquitylation (139). However, unlike CBP, GR ubiquitylation is not affected by Htt-
N63-99Q (Fig. 26B). Thus, the enhancement of CBP ubiquitylation by Htt-N63-99Q is 
selective and does not represent an overall increase in ubiquitin conjugation or 
proteasome inhibition. 
 
5. Mechanisms underlying the selectivity of enhanced CBP degradation  
 
Why is CBP selected by the UPP for accelerated degradation in the presence of Htt-N63-
99Q? There may be two possibilities. First of all, specific domains of CBP may bind to 
polyQ-expanded htt and recruit CBP to the UPP. As mentioned earlier, both polyQ 
domain of CBP and its HAT domain are candidates for this interaction. Secondly, the 
selectivity of CBP degradation may be due to the activation of specific E2 ubiquitin 
carrier proteins or E3 ubiquitin ligases, both of which function to target proteins to the 
UPP. 
 
5. 1 The effect of Htt-N63-99Q on expression of CBP deletion mutants 
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As previously mentioned a number of transcriptional factors or cofactors have Q-rich 
regions such as Sp1 and p300 (81). The mouse CBP also contain a polyQ region in which 
there is 15 consecutive Qs (47). As shown in Figure 16, Sp1 is not recruited into the 
aggregates, nor does it display any loss-of-staining. Nucifora et al. also showed that a 
polyQ-deletion mutant of CBP is not recruited into the aggregates. Therefore, we first 
wanted to examine whether deletion of the polyQ domain of CBP has an effect on its 
degradation.  
 
To test this possibility, we first used the same CBP∆Q construct as the one used in the 
paper by Nucifora et al. Before using this mutant, we have sequenced both the wide-type 
CBP and CBP∆Q constructs. Results indicate that the only difference between the two 
construct is the deletion of 15Q tract in the mutant. As shown in Figure 27A, the level of 
CBP∆Q is still decreased when cotransfected with 99Q versus 19Q htt (lane 3 and lane 
4), suggesting that the degradation of CBP is not Q-domain dependent.  
  
The CBP∆Q construct from Nucifora used in these initial studies is not a tagged version, 
therefore the transfected CBP can not be distinguished from endogenous CBP. 
Differences of CBP levels that can be detected are critically dependent on the transfection 
efficiency. To eliminate this problem, we used a flag tagged wild-type CBP construct and 
its counterpart Flag-CBP∆Q mutant. In the latter one, the 15 consecutive CAG repeats in 
the sequence were substituted with an EcoRI site. As shown in the Western blot of Figure 
27B, which is probed with an anti-flag antibody, there is a significant decrease of Flag- 
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Figure 27: Degradation of CBP is independent of its polyQ domain 
 In A, soluble protein extracts were prepared from HT22 cells transfected with a CBP 
(untagged) or CBP∆Q expression plasmid with Htt-N63-99Q or Htt-N63-19Q expression 
plasmid, and then subjected to Western blot analysis to detect total cellular CBP (top 
panels). Stripped blots were probed with an anti-lamin B (bottom panels) antibody to 
provide an internal control for protein loading. Decrease CBP levels in the presence of 
99Q instead of 19Q (i.e. lanes 1 and 2) is not altered when the polyQ domain of 
transfected CBP is deleted (i.e. lanes 3 and 4). In B, a Flag-CBP or a Flag-CBP∆Q 
construct was transfected with either Htt-N63-19Q or 99Q. Western blots were probed 
with an anti-flag antibody. The results are similar with those from panel A. Furthermore, 
when tagged versions of the constructs were used, the decrease of CBP or CBP∆Q level 
is more obvious than with untagged versions where endogenous CBP is also detected in 
Western blots. . Right panels (C.D) showed quantitative analysis, in which data were 
collected from three independent experiments.  
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CBP level when it co-expressed with Htt-N63-99Q (lane 1 and lane 2). A similar 
decrease is observed for Flag-CBP∆Q expression. This figure clearly indicated that the 
degradation of the CBP is not simply dependent on its polyQ domain, which may be 
important for binding with Htt-N63-99Q. Since Nucifora et al. showed that CBP∆Q is not 
recruited into the aggregates, we still need to confirm whether Flag-CBP∆Q is recruited 
into 99Q aggregates in our system by IIF. If not, it may suggest that the polyQ domain is 
responsible for recruitment but not degradation. 
 
Next, we set out to examine whether the degradation of CBP is dependent upon its HAT 
domain. Since the HAT domain is quite large, we selected only a partial HAT deletion 
according to the results from Steffan et al, as shown in Figure 7. The region that has the 
strongest affinity for polyQ expanded htt mutant is the fragment starting from amino 
acids 1459 to 1877. Therefore, we made an in-frame deletion mutant from the Flag-CBP 
in which about the same region is deleted (amino acids 1446-1866). As the preliminary 
data shown in Figure 28, expression of Flag-CBP∆HAT (about 219kD) is still reduced 
when coexpressed with 99Q. Therefore, this region is still not required for increased 
degradation of CBP in the presence of 99Q.   It has been reported that a well-conserved 
bipartite nuclear localization signal localizes within the deleted region (120). However, 
our IIF staining study showed that Flag-CBP∆HAT maintained the diffused nuclear 
staining in HT22 cells (data not shown).  
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Figure 28: Degradation of CBP is independent of its HAT domain 
 A Flag-CBP or a Flag-CBP∆HAT construct was transfected with either 19Q or 99Q 
plasmid construct, and then subjected to Western blot analysis to detect CBP by an anti-
flag antibody (top panel). Stripped blots were probed with an anti-lamin B (bottom panel) 
antibody to provide an internal control for protein loading. Comparing lane 3 and 4, 
decrease of CBP level in the presence of 99Q instead of 19Q is not altered when the 
amino acids 1446-1866 (which consists of part of the HAT domain) of transfected CBP is 
deleted. This result is preliminary and needs to be repeated.  
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5.2 Does Mdm2 play a role in polyQ-induced degradation of CBP?  
Mdm2 is an E3 ubiquitin ligase that has been linked to the CBP/p300 family of 
coactivators (119). It is reasonable to suspect that Mdm2 may be the E3 that targets CBP 
for degradation for the following reasons. There is an Mdm2-binding site on the N-
terminus of CBP. Furthermore Mdm2, p53 and CBP function as a complex to increase 
the degradation of p53 (119). We hypothesize that Mdm2 may be the E3 that targets CBP 
for degradation. If it is true, Mdm2 may be activated and accelerates the degradation of 
CBP in Htt-N63-99Q expressed HT22 cells. To test these hypotheses, we co-transfected 
HT22 cells with CBP (not tagged), Mdm2 and either 19Q or 99Q plasmids. As the shown 
in Figure 29, in cells transfected with 19Q, overexpression of Mdm2 reduced CBP levels 
to 23% (lane 1 and 3). In cells transfected with 99Q, Mdm2 had a smaller effect on CBP 
level (45%). These preliminary results suggest that in normal cells (i.e. cells expressing 
19Q), Mdm2 may be the specific E3 for CBP and that polyQ-expanded htt may block its 
activity. However, this result is preliminary and needs to be repeated. We still can not 
assess whether Mdm2 plays a role in CBP degradation in polyQ expressed cells. The use 
of a dominant-negative mutant of Mdm2 may aid these studies.   
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Figure 29: The effect on CBP level by the overexpression of Mdm2 in cells 
transfected with htt constructs  
HT22 cells were transciently transfected with CBP (untagged), control or Mdm2 and 
either Htt-N63-19Q or 99Q plasmic constructs, and then subjected to Western blot 
analysis to detect CBP by an anti-CBP antibody (top panel). Stripped blots were probed 
with an anti-lamin B (middle panel) antibody to provide an internal control for protein 
loading. The blot is also reprobed with anti-Mdm2 to confirm the expression as shown in 
the bottom panel. In lanes 1 and 2, CBP level is decreased in the presence of 99Q 
comparing to 19Q (58%). Comparing lane 1 and 3, overexpression of Mdm2 decreased 
the level of CBP at the presence of 19Q (23%). Comparing lane 2 and 4, overexpression 
of Mdm2 had a smaller effect on CBP level at the presence of 99Q (45%).  
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IV DISCUSSION 
 
1. CBP is a target of polyQ-expanded proteins 
 
A number of studies have implicated the CBP coactivator as a selective target of polyQ-
expanded proteins inclusion htt, atrophin-1, AR and ataxin 3 (47, 82, 120, 128). CBP is 
essential for neuronal cell survival through its impact on various transcription factors with 
established prosurvival effects in neurons, such as CREB (47, 82, 118, 121, 128). The 
most exciting evidence to support the relevance of CREB function in HD is from a recent 
study using a conditional mouse model containing a double knockout of CREB and 
cAMP-responsive element modulator (CREM) in postnatal forebrain. Mice with a 
CREB/CREM double knockout showed progressive neurodegeneration in the dorsolateral 
striatum and the hippocampus, reminiscent of Huntington disease (21).  Upon the 
recruitment of CBP into nuclear aggregates containing polyQ-expanded protein, CBP 
function is disrupted, leading to reductions in transcription from CREB target genes (47, 
149). Evidence of a decrease in CREB mediated transcription is obtained from two types 
of analyses. This first uses CRE reporter assays in cell culture systems, where CRE-
mediated transcription was shown to be decreased (149). In addition to CBP, other 
transcriptional factors such as TAFII130 may also be responsible for the decrease of 
CRE-dependent transcription (46, 83). Therefore the disruption of CREB mediated 
transcription may result from the dysfunction of multiple proteins.  PolyQ-expanded 
protein effects on CRE-dependent genes have also been examined in vivo. Some cAMP 
responsive genes such as somatostatin and corticotrophin releasing hormone are found to 
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have reduced expression in early HD brain (153, 154). Furtherfore a few microarray 
analysis from cell culture or transgenic mice have identified a number of candidate 
CREB-responsive genes whose expression is altered by polyQ-expanded htt (149). The 
fact that CBP overexpression (47, 128) or elevations in cAMP (149) could rescue polyQ-
expanded htt or androgen receptor-mediated toxicity provides strong support for the 
notion that CBP can be limiting for neuronal cell survival. Although most studies have 
indicated recruitment of CBP into insoluble aggregates as the basis for its disrupted 
function, it may also be possible that CBP interacts with the soluble polyQ expanded 
proteins.  
 
Along with other coactivators, CBP exerts its affects on transcription through the 
recruitment of histone acetyltransferases (48). The relevance of this CBP activity for 
neuronal cell survival is suggested by the observed inhibition of polyQ protein-dependent 
toxicity when histone acetylation is restored upon inhibition of histone deacetylases (48). 
Histone deacetylases such as trichostatin (TSA) and suberoylanilide hydroxamic acid 
(SAHA) are promising targets for drug development of HD and other polyglutamine 
diseases (28, 48). 
2. HT22 cell toxicity is associated with nuclear localization of polyQ-expanded htt 
Nuclear localization of polyQ-expanded proteins appears to be important for triggering 
neuronal cell death (35, 58, 78, 155), although in some cases polyQ-expanded proteins 
localized within the cytoplasm can also contribute to toxicity (59, 156, 157). In the HT22 
hippocampal cell line, we find that toxicity within individual cells induced by polyQ-
expanded htt, as revealed by a TUNEL assay, is associated with either nuclear or 
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perinuclear aggregates. HT22 cells that contain cytoplasmic polyQ-expanded htt 
aggregates exhibit minimal signs of cell death under our culture conditions. Likewise, 
CBP loss or its recruitment into polyQ-expanded htt aggregates only occurs in HT22 cells 
containing nuclear or perinuclear aggregates. These results suggest that, as in other cell 
types examined (47), disruption of CBP function in an important determinant of polyQ-
expanded htt toxicity.  
3. PolyQ-expanded htt can enhance CBP processing by the UPP 
While CBP recruitment into polyQ-expanded htt aggregates is one mechanism that serves 
to limit its function, we show here that loss of CBP protein, probably via degradation, 
could provide another mechanism that contributes to polyQ-expanded htt toxicity. In 
previous studies, CBP was found to co-localize with polyQ-expanded disease proteins in 
nuclear aggregates (47, 82, 128). Recruitment of CBP into polyQ-expanded protein 
aggregates has also been observed in brain tissue from polyQ repeat disease patients and 
transgenic mouse models of these diseases (47, 82, 128). While CBP is also recruited into 
polyQ-expanded htt protein aggregates in HT22 cells, CBP degradation appears to 
accompany the formation of nuclear htt aggregates in a relatively large fraction of HT22 
cells (i.e. up to 40%). The loss of CBP staining was also observed in another 
neuroblastoma cell line (i.e. N2a cells) expressing htt nuclear aggregates and thus is not 
strictly a property of HT22 cells. Our results do not definitively exclude the possibility of 
polyQ-expanded htt effects on CBP gene expression, but two independent assessments of 
UPP action on CBP (see below) support a role for enhanced degradation contributing to 
CBP loss.  
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Aggregation of polyQ-expanded proteins within cells has been found to reduce 
proteasome function and contribute to toxicity (33, 85). However, we find that in many 
cells expressing htt aggregates, CBP expression is reduced, owing in part to its 
degradation by the UPP. The recovery of CBP expression by proteasome inhibition in 
polyQ-expanded htt expressing cells supports this notion. Thus in addition to acting to 
block proteasome activity through the recruitment of essential proteasome components 
into nuclear aggregates (33, 85), polyQ-expanded proteins may also specifically enhance 
proteasome-dependent degradation of select substrates (e.g. CBP). This possibility could 
reflect increased activity of some component of the UPP or altered conformation of 
polyQ-bound CBP leading to engagement of the ubiquitylating enzymes or the 
proteasome. In fact, we find increased CBP ubiquitylation in HT22 cells expressing 
polyQ-expanded htt. Thus, some fraction of CBP appears to be more effectively engaged 
with the UPP in cells expressing polyQ-expanded htt. CBP degradation was observed in 
cells that express Htt-N63-99Q nuclear aggregates, although we cannot rule out the 
possibility that enhancement of proteasome activity can accompany the accumulation of 
toxic polyQ-expanded proteins that are not visibly associated with aggregates (35, 58). 
Furthermore, the toxic form of polyQ-expanded htt may be an unfolded intermediate (34) 
that alters the conformation of associated CBP and thereby enhances its targeting to the 
UPP prior to the formation of visible aggregates. For example, Gines S et al. reported that 
decrease of CRE-signaling in striatum of a HD mouse model occurred preceding 
aggregate formation (158). 
Expression of polyQ-expanded htt can have a positive impact on protein degradation 
through an enhancement of proteasome subunit expression (159) or stimulation of 
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endosomal-lysosomal activity (160). In differentiated N2a neuroblastoma cells, ubiquitin 
conjugation can be detected on both normal and polyQ-expanded htt, although 
proteasome-mediated degradation of the ubiquitylated polyQ-expanded htt is selectively 
impaired (85). Thus, it is conceivable that the UPP could be activated in cells expressing 
polyQ-expanded htt but restricted in its action towards substrates (e.g. CBP) that are 
efficiently targeted to proteasomes following their ubiquitylation. While there is a 
reduction (i.e. 40%) in soluble proteasome activity in differentiated N2a cells expressing 
htt with an expansion containing 150 glutamines, proteasome activity in a pelleted 
fraction is dramatically enhanced (i.e. 10-fold) upon expression of this polyQ-expanded 
htt (85). Within an organelle (i.e. the nucleus) where proteasome action may typically be 
limited (161), any recruitment of proteasome subunits could enhance the degradation of 
potential substrates, prior to the eventual limitation of proteasome function through their 
sequestration into polyQ protein aggregates.  
Not all nuclear proteins may share sensitivity to presumed activation of the UPP by 
expanded polyQ htt, as exhibited in our studies by the apparent lack of effects of polyQ-
expanded htt nuclear aggregates on Sp1 localization and expression. PolyQ-expanded htt 
effects on Sp1 function do not require UPP involvement, but rather are due to a 
sequestration of Sp1 from productive interactions with both its cognate DNA recognition 
sites and the TAFII130 transcription factor (46). Furthermore, the enhancement of CBP 
ubiquitylation is selective since polyQ-expanded htt did not affect ubiquitylation of 
another proteasome substrate in HT22 cells, i.e. the GR protein. Since pharmacological 
inhibition of the proteasome increased both GR and CBP ubiquitylation in HT22 cells, the 
lack of enhanced GR ubiquitylation in cells expressing polyQ-expanded htt demonstrates 
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that proteasome function is not uniformly inhibited upon expression of polyQ-expanded 
htt. In a transgenic mouse model of SCA1, turnover of the protein kinase C delta isoform 
was increased in Purkinje cells of the cerebellum (162). In contrast, cerebellar Purkinje 
cell expression of the mGluR1 metabotropic glutamate receptor subunit protein was not 
affected in the SCA1 mice (162). Thus, selective enhancement of protein degradation 
may be a feature of other polyglutamine diseases and contribute at various levels to 
disease progression.  
Although previous studies showed that either the polyQ domain of CBP or its HAT 
domain interact with polyQ-expanded htt (48), we are unable to detect an effect of those 
domains on the degradation of CBP by using corresponding deletion mutants. Thus, 
neither the polyQ nor HAT domain alone may be sufficient for binding to polyQ 
expanded htt. Other domains or a combination of more than one domain may be required. 
Alternatively it is possible that it is not the interaction of CBP and polyQ-expanded htt, 
but rather selective activation of the E3 ligase who targets CBP to UPP which triggers 
enhanced CBP degradation. As shown by our data in Figure 29, Mdm2 may be involved 
in the degradation of CBP under normal conditions. Therefore, the CBP-Mdm2 
interaction domain may be important for the degradation of CBP induced by polyQ-
expanded htt. This possibility could be tested by examining htt effects on CBP mutants 
lacking this domain. 
Although nuclear dysfunction is devastating to cells expressing polyQ-expanded proteins, 
deficits of cytoplamic and neruite functions may also contribute to toxicity. For example, 
Sapp et al. showed that in lower grade HD patients, at the time that no nuclear aggregates 
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were detected in the striatum, mutant htt had accumulated in both the cytosol and axons 
of extensive striatal and cortical areas (60). This finding suggests that dysfunctions in 
axons may be an early event in HD pathogenesis. Several other studies also showed that 
neruite outgrowth and synaptic plasticity were affected before detectable nuclear changes 
in polyQ-expanded htt expressed cells (163). The cytoplasmic and synaptic dysfunctions 
can be induced by several mechanisms such as the presence of cytoplamic aggregates and 
decreased transcription of synaptic protein genes (164).   It may also result from the 
enhanced degradation of related proteins in the presence of polyQ-expanded proteins 
through UPP, which has been shown to degrade some synaptic proteins. For example, 
human Siah proteins, which are putative E3 ligase, were shown to trigger degradation of 
the synaptic protein synaptophysin (165). Furthermore, the synaptic vesicle protein Ves1-
1S/Homer-1a has an increased level and accumulates in vesicles upon proteasome 
inhibition (166). Therefore, altered UPP function on protein degradation in the presence 
of polyQ-expanded proteins may not be restricted to only nuclear proteins. As previously 
mentioned, in a SCA-1 transgenic mouse model, there is an obvious reduction of PKCγ 
that is normally located in cytoplasm or the dendrites of Perkinje cells (162). This 
reduction may primarily result from its enhanced degradation since only a minor decrease 
of PKCγ mRNA levels is observed. This degradation is also selective since mGluR1 
protein levesl are not reduced (162). Morton et al. reported that complexin II, a 
cytoplasmic protein involved in neurotransmitter release, was depleted in both a HD 
transgenic mouse model and HD postmortem patient’s brains (167). The reduction of 
protein level is not accompanied by the decrease of its mRNA level in the mice, 
suggesting that enhanced degradation of complexin II could be triggered by polyQ-
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expanded htt. In contrast, complexin I protein levels were not changed (167). Therefore, 
it will be also interested to examine whether the loss of PKCγ in the SCA1 model and 
complexin II in the HD model was also due to the enhanced ubiquitylation and selective 
degradation through the UPP, as what we have seen for CBP.  
Cell culture and transgenic models of polyQ repeat diseases have been informative and 
provided important insights into the molecular mechanisms contributing to neuronal cell 
death in these diseases. However, given the protracted time course of polyQ repeat 
disease progression in humans, there are likely to be many biochemical changes that 
occur over many years that contribute to the selective neuronal cell vulnerability that is 
characteristic of these diseases. The UPP is clearly critical to the cell function at many 
levels and therefore requires precise regulation to maintain its appropriate action. As 
shown in this report, opposing effects of polyQ-expanded htt on proteasome action can 
ultimately have comparable detrimental effects on neuronal cell survival. The ubiquitin–
proteasome pathway could therefore be involved at many levels during the progression of 
chronic neurodegenerative diseases. 
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CHAPTER III 
RESCUE OF POLYGLUTAMINE EXPANDED HUNTINGTIN BY 
MOLECULAR CHAPERONES 
 
I. INTRODUCTION 
 
1. Molecular chaperones 
 
Molecular chaperones are proteins that can facilitate protein folding and prevent 
or reverse protein misfolding or aggregation (65). They mainly function in two stages 
during protein metabolism. First, they bind to the nascent polypeptides which have not 
emerged from the ribosome. The binding of molecular chaperones facilitates their proper 
folding into higher order structures while avoiding improper aggregation (62). Molecular 
chaperones also play multiple roles in maintaining proper functioning of mature proteins. 
For example, when cells are under stress, molecular chaperones function to refold 
denatured proteins and avoid aggregation (62). When chaperones are unable to 
implement these functions, they can accelerate degradation of the denatured or 
aggregated proteins through their connection to the UPP. In addition, chaperone proteins 
are involved in other cellular process such as hormone function through regulating the 
translocation of certain nuclear receptors [reviewd by (62)]. 
 
Two well-understood families of chaperones are DnaK and DnaJ families that are 
conserved among species from eukaryotic bacteria to mammals. Hsc70/Hsp70 are 
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members of DnaK family chaperones in mammalian cells. Hsc70 is the constitutive form 
and Hsp70 (heat shock protein 70) the inducible form of this protein family. Hsp70 has 
intrinsic ATPase activity and binds with the unfolded peptides mostly through 
hydrophobic interactions (168). The HDJ-1 (Hsp40) and HDJ-2 are mammalian members 
of DnaJ family proteins. They are cochaperones of DnaK family proteins and regulate 
their ATPase activities (65). Figure 30 shows a simplified representation of how an 
Hsp70/Hsp40 interaction cycles facilitate the folding of unfolded polypeptide in an ATP-
dependent manner. The mechanism also applies to the process of refolding denatured 
proteins. Binding of Hsp40 with Hsp70 stimulates the ATPase activity of Hsp70. The 
ADP-bound form of Hsp70 has an increased affinity for unfolded protein (169). Hsp40 
also binds to hydrophobic peptides and targets them to Hsp70 (170). ADP-bound Hsp70 
aids in the appropriate folding of bound-peptides. Once nucleotide exchange factors 
facilitate the replacement of ADP with ATP (such as Bag-1), the folded peptide is 
released, and Hsp70 and Hsp40 resume a new reaction cycle (170).  
 
2. Molecular chaperones and polyglutamine diseases 
 
A number of neurodegenerative diseases involve deposition of mutant protein formed 
extra or intracellular aggregates (28), suggesting inappropriate folding of the disease 
proteins. In addition, affected neurons are under multiple cellular stresses. Therefore, 
molecular chaperones can perform various functions that limit neurodegenerative
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Figure 30: Hsp70/DnaJ reaction cycle  
DnaK family molecular chaperones have ATPase activatity. The ADP bound state of 
Hsp70 has an increased affinity with the unfolded polypeptides and fold them. Once ADP 
is exchanged by ATP on Hsp70, the well-folded peptides are released. DnaJ family 
molecular chaperones can stimulate the ATP hydrolysis of DnaK and therefore facilitate 
peptide folding. Nuclear exchange factors such as Bag-1 indicated in this figure have 
opposite functions. 
 
Table 5: Possible functions of molecular chaperones in neurodegenerative diseases 
Adapted from (62) 
Prevent aggregation of mutant proteins such as polyQ-expanded htt 
Prevent aggregation and promote refolding of damaged proteins under cellular stress 
Promote the solubility of aggregated proteins including those that are trapped by the 
     aggregated proteins 
Sort abnormal proteins for ubiquitylation and degradation if they can not be well-folded 
Suppress apoptotic programs  
Facilitate correct folding and glycosylation of membrane and secreted proteins 
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conditions.  As reviewed by Sherman and Goldberg, Table 5 summarizes the possible 
roles chaperones may play to prevent aggregation and improve cellular survival (62). The 
roles of molecular chaperones in polyglutamine diseases were initially studied by 
Cumming et al. (29). They found that overexpression of HDJ-2 was able to reduce the 
formation of NI containing polyQ-expanded atxin-1 in tranfected Hela cells. Furthermore 
HDJ-2 was recruited into the nuclear aggregates of SCA-1 patients’ brains (29). Since 
this study, numerous studies have tested the roles of DnaJ family and other chaperones in 
different polyglutamine diseases. Subsequently, more chaperones proteins have been 
examined for their roles in polyglutamine diseases in different disease models including 
neuronal and nonneuronal cell lines, transgenic mice and patients’ brains (65). Despite 
the general consensus that molecular chaperones are involved in reducing the aggregation 
and toxicity of polyQ proteins, results are very variable (Table 6). For example there is 
variability in chaperones rescue within different cell lines. Furthermore there is often a 
dissociation of chaperone rescue of aggregation versus toxicity (Table 6). To confirm the 
value of chaperones in rescuing polyQ induced toxicities, additional evidence has been 
obtained from in vivo assays, especially from double transgenic models. Some of these 
results are summarized in Table 7 by Sakahira H et al. (65). For example, in a polyQ 
transgenic Drosophila eye model, a P-element directed screen identified dHdj-1 and 
dTPR2 (both contain J-domain) as suppressors of polyQ toxicity in Drosophila retinal 
neurons. (171). In a SCA-1 double transgenic mouse model, overexpression of inducible 
Hsp70 chaperone suppresses neuropathology and improves motor function in mice 
without effect on aggregation (172). These in vivo studies confirm that molecular 
chaperones are promising targets for therapeutic strategies for polyglutamine diseases. 
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Table 6: A summary of chaperone rescue of polyQ aggregation and toxicity in 
polyglutamine repeat diseases in cell culture and transgenic mice 
 
PolyQ disease 
(protein-polyQ) 
Results of chaperones rescue of polyQ induced 
toxicity in vitro 
Reference 
   
SCA1 
(ataxin1/polyQ) 
HDJ-2 colocalized into polyQ aggregate in mouse 
and cell culture. HDJ-2 rescues aggregation in cell 
culture.  (Hela cells) 
(29) 
   
SBMA 
(AR-polyQ) 
HDJ-2 is colocalized into polyQ aggregates and 
rescues aggregation  (Hela cells) 
(173) 
   
SBMA  
(AR-ployQ) 
Hsc70/HDJ-1 combination or hsc70 alone rescue 
aggregation and apoptosis. HDJ-2 is unable to rescue 
aggregation and apoptosis (N2a cells) 
(147) 
   
HD 
(htt-polyQ) 
HDJ-2 increase aggregation in a certain cell type 
(Cos7 cells but not PC12 cells) 
(174) 
   
HD  
(htt-polyQ) 
HDJ-2 and hsc70 colocalize with polyQ aggregates 
in transgenic mice.  Only HDJ-1 and/or hsc70 rescue 
polyQ aggregation and toxicity. (N2a cells) 
(85) 
   
SCA3  
(ataxin3-polyQ) 
HDJ-1, HDJ-2, Hsp70 colocalized into the polyQ 
aggregate in patient brains. HDJ-1 rescues 
aggregation and toxicity in cell culture. HDJ-2 
rescues aggregates but not toxicity (Cos7cells and 
PC12 cells) 
(148) 
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Table 7:   Effects of molecular chaperones on polyQ aggregation and toxicity in vivo 
      Adapted from (65) 
 
Chaperones 
 
Organisms 
 PolyQ 
disease  Aggregation Toxicity
Domain of 
mutation References 
Hsp70  Mouse  SCA-1 no change decrease  (172) 
dHdj-1  Drosophila  PolyQ no change decrease  (171) 
dTPR2  Drosophila  PolyQ no change decrease  (171) 
dHsp70  Drosophila  SCA-3 no change decrease  (68) 
dHsp70 (D/N)  Drosophila  SCA-3 n.d. increase ATP-binding 
domain 
(68) 
dHdj-1   Drosophila  SCA-3 n.d. decrease  (175) 
dHdj-1 (D/N)  Drosophila  SCA-3 n.d. increase J-domain 
deletion 
(175)  
dHdj-1 (D/N)  Drosophila  SCA-3 n.d. increase Substrate 
binding 
domain 
(175) 
dHsp70 + dHdj-
1 
 
 Drosophila  SCA-3  no change 
under LM; but 
more soluble 
fraction by 
Western blot 
decrease 
more 
 (175) 
dHdj-1  Drosophila  HD n.d. decrease  (175) 
dHdj2  Drosophila  HD n.d. no 
change 
 (175) 
dHdj-1  Drosophila  SCA-1  more compact decrease  (176)  
n.d., not determined; D/N, dominant-negtive 
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However, as shown in higher organisms, molecular chaperones appear to rescue toxicity 
but not necessarily on aggregation of polyQ-expanded proteins (Table 7). In this part of 
the dissertation, we have examined chaperone function in both in vivo and in vitro 
models of HD and confirmed that chaperone overexpression is not always sufficient for 
rescue of NI formation. 
 
II. MATERIAL AND METHODS 
 
1. Plasmids 
The plasmid p6R flag-HDJ-2/HSDJ encodes the full-length human HDJ-2 that is tagged 
with a flag epitope at its N-terminus. The plasmids pcDNA3.1-Htt-N63-19/99Q-myc-His 
have been decrible in the methods section of chapter II.  
 
2. Cell culture, transfection, Western blot analysis and IIF 
Human HEK 293 fibroblast cells were maintained in Dulbecco's modified Eagle medium 
(Invitrogen) supplemented with 10% FBS (Atlanta Biologicals) and 
penicillin/streptomycin (BioWhittacker). Transfection was performed using the 
lipofectamine reagent (Invitrgen) as decribed in Chapter II. Western blot analysis and IIF 
were performed as decribed in Chapter II. Mouse anti-Hsp70 antibody and rabbit anti-
Hsp40 (HDJ-1) antibody were purchased from Stressgen. Mouse anti-HDJ-2/DNAJ Ab-1 
(clone KA2A5.6) was purchased from Neomarkers.  
 
 
  116  
3. Animal model and immunohistochemistry of brain sections 
HD transgenic mice express Htt-N171-82Q, which contains the N-terminal 171 amino 
acids with an 82Q expansion. Brains were obtained from transgenic mice that were 4-5 
months old. Control mice of the same age were killed, sectioned and examined at the 
same time. After dissection, brains were treated with PFA, sectioned at 30-40 µm coronal 
plane and stored at -20°C. For brain staining, sections from whole brains were washed 
with PBS and then incubated with primary antibody diluted in PBS supplemented with 
donkey serum at 4°C overnight. The next day, sections were washed with PBS and then 
incubated with secondary antibodies followed by avidin-biotin complex at room 
temperature for 2 and 1.5 hours, respectively. Finally, the sections were reacted with 
diaminobenzidine (DAB) (Sigma) for 10 minutes and then hydrogen peroxide (Sigma). 
The reaction was terminated by washing with fresh buffer. All the sections were mounted 
and examined under light microscopy.  The mouse anti-htt antibody is made against the 
N-terminal 17 amino acids of htt and was provided by Dr. Christopher Ross of John 
Hopkins University.  
 
III. RESULTS: 
 
1. Overexpression of HDJ-2 does not reduce the formation of aggregates containing 
polyQ-expanded htt in HEK 293 cells 
 
We first selected human HEK293 embryonic kidney cell line to assess the ability of HDJ-
2 to rescue aggregation of polyQ expanded htt. Overexpressed Htt-N63-99Q in 
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transiently transfected HEK293 cells exhibit primarily three patterns: diffuse cytoplasmic 
staining, nuclear aggregates and cytoplasmic aggregates. Htt-N63-19Q consistently 
displayed diffused cytoplasmic staining in transfected cells.  
 
As HDJ-2 was shown to reduce aggregation of ataxin-1 in Hela cells (29), we first 
examined whether it could also decrease aggregation of Htt-N63-99Q in our cell system. 
Therefore, we cotransfected a flag-HDJ-2 construct with Htt-N63-99Q into HEK 293 
cells and examined Htt-N63-99Q aggregates. As shown in Figure 31 and summarized in 
Figure 32A, Flag-HDJ-2 did not reduce the number of Htt-N63-99Q expressing cells 
containing aggregates, although HDJ-2 was recruited into the aggregate in a majority of 
the 99Q aggregate containing cells (Figure 32B). To exclude that the inability of HDJ-2 
to rescue aggregation was due to its inadequate expression, we performed the following 
experiments. As shown in Figure 32B, we confirmed that Flag-HDJ-2 is expressed in 
96% of the cells expressing 99Q.  An elevation of the ratio of HDJ-2 to 99Q DNA to 5:1 
in transfection experiments was still unable to reduce the aggregation. We also perform 
Western blots to show that the total HDJ-2 amount is increased about 1.8 folds (Figure 
33). Given the 10-20% transfection efficiency, this amount of HDJ-2 increase represents 
only a minimum estimation of overexpression within individual cells. Therefore, we 
conclude that overexpression of HDJ-2 can not rescue the formation of aggregates 
containing 99Q in HEK293 cells. This result is consistent with other published papers 
which showed that HDJ-2 can not rescue polyQ-expanded huntingtin aggregates in 
neuronal and nonneuronal cell lines (Table 7) (85, 174). We also tested other chaperones 
such as Hsp70 and HDJ-1. Neither can rescue polyQ-htt aggregation (data not shown).   
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Figure 31: Colocalization of Htt-N63-99Q protein with cotransfected flag-HDJ-2 in 
HEK293 cells  
HEK293 cells were cotransfected with 1 µg of the Htt-N63-99Q DNA and 5µg of flag-
HDJ-2.  Cells were processed for IIF using a rabbit anti-c-myc and a mouse anti-flag 
antibody, and then examined by confocal fluorescence microscopy.  Red staining shows 
the Htt-N63-99Q protein, while green staining shows the HDJ-2 protein.  The areas of 
overlap are depicted in yellow. In the lower three cells, although HDJ-2 is overexpressed, 
aggregates containing 99Q does not disappear. Note that HDJ-2 can be recruited into 
these aggregates.  
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Figure 32: Overexpression of HDJ-2 does not rescue 99Q aggregate formation  
Cells from randomly selected fields were counted following IIF. Panel A (left columns) 
shows the percentage of cells containing aggregates or with cytoplasmic staining when 
1µg Htt-N63-99Q was transfected. The right columns show the percentage of cells 
containing aggregates when 1µg 99Q and 5µg flag-HDJ-2 were cotransfected. There is 
no difference between the two groups. Panel B shows the percentage of cells with 
different staining patterns when 99Q and HDJ-2 were cotransfected (panel right 
columns). Note that when 99Q is present within aggregates, most of the cells also express 
HDJ-2 in the aggregates. These experiments have been repeated at least three times.  
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Figure 33: Overexpression of HDJ-2 in cells cotransfected with Htt-N63-99Q  
HEK 293 cells were transfected with control or Htt-N63-99Q with HDJ-2 plasmid 
vectors. Western-blot analysis was performed to detect HDJ-2 level using an anti-HDJ-2 
antibody. The level of total HDJ-2 is increased about 1.8 folds upon the transfection of 
flag-HDJ-2 (comparing lanes 2 and 3). 
  121  
2. Molecular chaperone recruitment into aggregates containing Htt-N63-99Q in 
transfected cells 
 
Although HDJ-2 was unable to rescue polyQ-htt aggregate formation, it was recruited 
into the aggregates in 80% of cells expressing 99Q aggregates (Figures 31 and 32B). This 
prompted us to examine expression of endogenous HDJ-2 and other chaperones including 
HDJ-1 and Hsc70 in cells expressing 99Q aggregates. As shown in Figure 34, 
endogenous HDJ-2 is also recruited into nuclear aggregates. Thus, the recruitment of 
HDJ-2 to 99Q aggregates in vitro is not sufficient to ensure rescue of aggregates.  In 
contrast to the recruitment of HDJ-2, 99Q aggregates in transfected HEK293 cells do not 
recruit endogenous HDJ-1. HDJ-1 remains predominantly cytoplasmic and seems to be 
excluded form the aggregates with minimal colocalization. Hsc70 localization changes 
slightly in cells expressing 99Q, as some Hsc70is recruited to the nuclear aggregates. 
However, the major fraction of Hsc70 remains in the cytoplasm.   
 
3. Molecular chaperone recruitment into aggregates containing polyQ-expanded 
huntingtin in a transgenic mouse model of HD  
 
HDJ-2 and Hsc70 were detected in the ataxin-1 aggregates of cerebellum Perkinje cells in 
both patients’ brain and a transgenic mouse model (29). Therefore, we examined whether 
molecular chaperones are recruited into aggregates formed in a HD transgenic mouse 
model. The mouse model we used is derived from the R6/2 strain. These mice bear a  
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Figure 34: Recruitment of endogenous HDJ-2, HDJ-1 and Hsc70 into Htt-N63-99Q 
aggregates. HEK293 cells were transfected with 2.5µg of Htt-N63-99Q DNA and then 
costained with rabbit anti-c-myc and mouse anti-HDJ-2 antibodies (panel A), mouse anti-
HDJ-1 (panel B), or rat anti-Hsc70 (panel C). Cells were examined under confocal 
fluorescence microscopy.  The red shows Htt-N63-99Q protein, while the green shows 
endogenous HDJ-2, HDJ-1 or Hsc70.  The areas of overlap are depicted in yellow. Panel 
A is a triple overlay of red, green immunofluorescence and differential interference 
contrast microscopy (DIC). Endogenous HDJ-2 is recruited into 99Q-containing 
aggregates. HDJ-1 localizes predominately within the cytoplasm and is only minimally 
recruited into the 99Q containing aggregates. Hsc70 is partially recruited into 99Q-
containing aggregates. 
 
 
 
 
  123  
     
 
 
Figure 35:  Hsc70, HDJ-1 and HDJ-2 expression in the brain of HD transgenic mice bearing Htt-N171-82Q (R6/2 strain). 
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Legends of Figure 35: Brain sections from transgenic mice bearing Htt-N171-82Q were 
stained with antibodies to either ubiquitin, the N terminus of human huntingtin, Hsc70, 
HDJ-1 or HDJ-2. Certain areas which are most affected by the mutant protein are shown 
here (i.e. cerebellum, CA1 and CA3 fields of the hippocampus). Note that neither HDJ-1 
nor HDJ-2 was recruited into the htt-containing aggregates. Some recruitment of Hsc70 
was observed. No aggregates were seen in control mice brain sections stained with 
antibodies against ubiquitin, huntingtin or Hsc70 (Data not shown). 
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transgene encoding the N terminal 171 amino acids of htt within which there is an 82 
polyQ tract (Htt-N171-82Q). The control mice bear an 18Q instead (Htt-N171-18Q).  
This mouse line has been well studied and the 82Q mice showed HD like phenotypes 
(92). NI were also detected in multiple sites of the brain including cortex, hippocampus 
and at a late stage, striatum (92). The Htt-N171-82Q mice at 4-5 months of age show 
neurological deficits such as tremor, loss of weight and uncoordination. This line of mice 
normally die at 5-6 months of age (92).  
 
Before examining chaperone recruitment, we first looked at brain regions that contain 
aggregates by using an anti-htt antibody and an anti-ubiquitin antibody, respectively in 4-
month old mice. The most obvious regions with aggregates are cerebral cortex, 
hippocampus (CA1 and CA3) and cerebellum. As shown in Figure 35, aggregates 
containing 82Q were detected in these regions that also contain ubiquitin. Therefore we 
stained these regions with antibodies against individual chaperones. Unlike what was 
reported for SCA1 (29), HDJ-2 is not recruited into aggregates although HDJ-2 was well-
stained in the areas examined as diffused cytoplasmic staining. To exclude the possibility 
that our staining technique was unable to detect HDJ-2 in the aggregates, we obtained the 
same SCA-1 mouse tissue as published by Cumming et al.(29). We indeed detected HDJ-
2 in aggregates containing polyQ-expanded ataxin-1 using exactly the same antibody and 
staining procedures (data not shown). Therefore, we concluded that at least in the HD 
mouse brain, HDJ-2 is not recruited into aggregates containing polyQ-expanded htt at 
late stages of disease progression.  
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In addition to HDJ-2, we also examined the localization of HDJ-1 and Hsc70. As shown 
in Figure 35, HDJ-1 is not recruited into htt aggregates as well. However, we did detect 
recruitment of Hsc70 into aggregates in some cells. HDJ-1, HDJ-2 and Hsp70 were 
detected in aggregates in a SCA-3 mouse model as well (148). Comparing the SCA1 and 
SCA-3 mouse models with our HD model, it suggests that molecular chaperones may not 
react uniformly to different polyQ-expanded proteins in vivo. There is still no report of 
any chaperone recruitment into the aggregates of HD patients’ brains. 
 
IV DISCUSSION 
 
1. Limitation of in vitro assays of polyQ-expanded protein aggregation and toxicity 
As shown in Table 6, there is substantial viability of chaperone rescue of polyQ induced 
aggregation and toxicity. These differences may result from at least two reasons. The first 
is the inconsistency of cell lines used. Even in the same study, different cell lines may 
exhibit different abilities of chaperone rescue (Table 6). This may be due to variations of 
levels of endogenous chaperones or chaperone partners. For example, in some cell line 
tested, only an overexpression of both a member of DnaK protein and a member of DnaJ 
protein can rescue aggregation (85, 147). In addition, each cell type could be subject to 
different “stressful” conditions. The second inconsistency is the length of Q residues in 
the protein and their context. PolyQ repeat length has been shown to be positively 
correlated with aggregate formation and toxicity. The length of the truncation of htt also 
has an effect on aggregation and toxicity (145). Therefore, these factors may both affect 
on chaperone rescue in various in vitro assays. In our study, we used Htt-N63-99Q. 
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Another construct such as Htt-N171-82Q may be differentially sensitive to chaperones 
rescue.  
 
2. Dissociation of polyQ-induced aggregation and toxicity 
Despite the inconsistency concerning chaperone rescue in various in vitro models, studies 
using double transgenic flies and mice do suggest that molecular chaperones may 
function to reduce toxicity (Table 7) (65). These results suggest that molecular 
chaperones should be considered as potential targets for therapeutic drugs to treat polyQ 
diseases. However, as shown in Table 7, in mammals, rescue of toxicity often is not 
accompanied by reduction of aggregation (65). We found that in HEK293 cells 
overexpression of HDJ-2 can not rescue aggregation. It may be possible that HDJ-2 can 
rescue toxicity without apparent effects on aggregation. I have tried to measure toxicity 
using the luciferase assay described in the previous chapter (data not shown). The results 
showed that overexpression of chaperones did not rescue Htt-N63-99Q induced toxicity, 
as luciferase activity was increased in both 19Q and 99Q expressing cells at the same 
ratio. However, other methods to test toxicity may be useful. Alternatively, the inability 
of HDJ-2 to rescue both aggregation and toxicity in our HEK 293 cells may be due to the 
recruitment of HDJ-2. As reported by Bonini et al., proteins that physically interact with 
polyQ-expanded proteins in their polyQ transgenic fly model failed to rescue cells from 
toxicity (177). Therefore, the lack of recruitment of HDJ-2 into aggregates in our HD 
mouse model can not rule out the possibility that HDJ-2 may function to reduce toxicity 
in vivo.  
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In addition to polyglutamine diseases, Hsp70 can also reduce α-synuclein induced 
toxicity in a transgenic fly model of PD without a corresponding reduction of its 
aggregation (178). Thus, what are the bases for the dissociation of aggregation and 
toxicity? One possibility is that chaperones change the solubility of polyQ-expanded 
proteins without distinguishable morphological changes of aggregates as detected by light 
microscopy (177). For example, in a polyQ transgenic fly or a yeast model, 
overexpression of chaperones rescue polyQ induced toxicity, while no change is observed 
on aggregation by light microscopy. However, using Western blot and a filter-trap assays, 
the SDS-soluble fraction of polyQ expanded protein was found to be significantly 
increased by overexpression of Hsp70 and Hsp104, respectively (24, 177). By solublizing 
the polyQ-expanded poteins, other polyQ protein interacting proteins may also become 
more soluble in the presence of chaperones and resume their normal functions. CBP and 
Sp1 are good candidates for proteins whose function may be restored by chaperones. 
Therefore, two experiments could be performed to test these possibilities. The first is to 
compare the solubility of Htt-N63-99Q in the presence or absence of molecular 
chaperones using Western blot or filter trap assays. The second is to examine whether the 
activity of CBP is increased upon overexpression of chaperones.  
 
3. Mechanisms underlying chaperones rescue of polyQ-expanded protein induced 
toxicity 
 
As shown in Figure 2A, the physical forms of polyQ-expanded proteins that are toxic 
may not be restricted to amyloid-like aggregates (24, 65). Other intermediate forms may 
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be more toxic than large soluble aggregates. For example, β-structured monomer and 
oligomers may trap other interacting proteins more efficiently than large aggregates (24, 
65). Molecular chaperones may function at multisteps during the folding of polyQ- 
expanded proteins to reduce cellular toxicity (24, 65). 
  
In addition to their roles in the folding process, molecular chaperones may participate in 
other pathways to reduce cellular stress (Table 5). Bag-1 and Chip are proteins that 
interact with Hsp70 (179). Both can target Hsp70-bound protein intermediates to the UPP 
for degradation. In this way, Hsp70 can also eliminate certain misfolded proteins. 
Therefore different Hsp70 interacting proteins can sort misfolded proteins into folding or 
the degradation pathways (179). In addition, Hsp70 has also been reported to have anti-
apoptotic functions through either c-Jun NH2-terminal kinase (JNK) dependent or 
independent mechanisms (180).  It has been reported that the JNK pathway is activated 
by polyQ-expanded htt and contributes to apoptosis in a hippocampal cell line (112). 
Hsp70 can inhibit JNK activation through increasing the JNK phosphatase activity and 
thus repress apoptosis (62), which has been also reported in an in vitro model of HD 
(181). Hsp70 does not need its chaperone acitivity to inhibit JNK activation since an 
Hsp70 mutant deficient in substrate binding still functions by this mechanism (180). In a 
JNK-independent manner, Hsp70 may function at the apoptosome level to block 
apoptosis (182). The apoptosome is a large complex containing cytochrome c, dATP, 
Apaf-1 oligomer and procaspase 9 in which procapase 9 is activated (12). Activated 
caspase 9 then cleaves and activates caspase 3. It has been reported that Hsp70 binds to 
Apaf-1 and thus inhibits the recruitment of procapase 9 into the apoptosome to block the 
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activation of caspase 9 and caspase 3. The chaperone activity of Hsp70 is required in this 
process (182). This apoptosome-dependent anti-apoptotic function of Hsp70 may also 
play a role in its protection against polyglutamine and other neurodegenerative diseases.  
 
Given the abilities of molecular chaperons to rescue the toxicity in various in vivo models 
of neurodegenerative diseases, molecular chaperones may be one of the most promising 
targets for development of drugs to treat these diseases.  
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CHAPTER IV: 
SUMMARY AND CONCLUSION 
 
As discussed in the first chapter, the mechanism underlying pathogenesis of HD is very 
complicated. This dissertation study has added to the mechanisms in several aspects.  
 
I. TRANSCRIPTION DEFICIENCY - CBP 
In previously published papers, the loss of CBP function in polyglutamine diseases was 
normally explained as due to its recruitment into aggregates containing polyQ expanded 
proteins (47, 82, 128). As shown in Chapter II of this study, we showed another 
mechanism that may contribute to loss of CBP function, which is through enhanced 
degradation. This conclusion is supported by results showing increased ubiquitylation of 
CBP in the presence of 99Q (Figure 26) and the recovery of CBP levels by the treatment 
of htt-polyQ expressing cells with a proteasomal inhibitor (Figures 21 and 22). However, 
we have only detected this phenomenon in an immortalized cell line. In order to confirm 
the relevance of CBP degradation in vivo, we should next examine primary neurons and 
transgenic mouse brain tissues. Considering the long and complicated process of 
pathogenesis in HD mouse, CBP loss may be temporary. In addition, we should further 
identify other mechanisms underlying selective CBP degradation in HT22 cells 
expression polyQ-expanded htt. 
 
Transcriptional deficiency is one of most important mechanisms underlying the 
pathogenesis of polyglutamine diseases. Among numerous transcription factors and 
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cofactors that are involved, CBP is the best-studied. Most importantly, it is promising to 
target this mechanism for therapeutic strategies based on its effects on toxicity of 
manipulating the HAT activity. Histone deacetylase inhibitors have been shown to reduce 
polyQ-expanded htt induced toxicity in transgenic Drosophila eye (48). Interestingly 
some of these inhibitors are even in clinical trials for the treatment of other diseases such 
as SAHA in cancer treatment (48).  
 
II. IMPAIRMENT OF UPP IN HD 
The UPP no doubt plays important roles in polyglutamine diseases and other 
neurodegenerative diseases. It was suggested that the general inhibition of UPP by 
polyQ-expanded proteins contributes to toxicity. Based on the results of accelerated CBP 
degradation through UPP in HT22 cells expressing Htt-N63-99Q, we suggested that 
impairment of UPP may not only be restricted to its inhibition. UPP can be more 
activated as well and target specific proteins, such as CBP for degradation. This 
activation can be temporally restricted. For example, at the early stage of the disease, in 
the attempt to eliminate aggregation, activated UPP may be involved in the degradation 
of other important proteins. At later stages of the disease, recruitment of UPP 
components into insoluble aggregates would eventually reduce its normal function. 
Different effects on UPP can be spatially regulated as well. For example, the UPP may be 
activated in the aggregates and inhibited elsewhere (85). Since the degradation of certain 
proteins is the result of activation of some E2, E3 or proteasome subunits, there are 
multiple levels at which the UPP could be affected by polyQ-expanded proteins. In 
addition, as discussed in Chpter II, degradation of proteins in the cytoplasm and synapse 
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may also be important for cellular toxicity, especially as synaptic loss is found in early 
stages of HD (60).  
 
III. MOLECULAR CHAPERONES 
As discussed in chapter III, molecular chaperones play multiple roles to reduce cellular 
toxicity under different stressful conditions. They are shown to be beneficial for the 
reduction of toxicity in polyglutamine diseases as well. In contrast to the initial paper 
concerning ataxin-1 by Cumming et al. (29), we did not detect HDJ-2 rescue of Htt-N63-
99Q aggregation and toxicity in HEK293 cells, nor did we found the recruitment of HDJ-
2 into aggregates of our HD mouse model. These discrepancies could result from the 
inconsistency of in vitro assays, the dissociation between aggregation and toxicity, and 
methods used to examine insolubility of the polyQ-expanded proteins in the aggregates. 
In our in vivo and in vitro assays, individual chaperone may respond differently to the 
same cellular stress, such as the difference in recruitment of endogenous HDJ-1 and HDJ-
2 in HEK293 cells transfected with Htt-N63-99Q. 
 
IV. CONNECTING MOLECULAR CHAPERONES WITH UPP IN 
POLYGLUTAMINE DISEASES 
When cells are under stress, such as heat shock, the levels of several groups of proteins 
are increased. These proteins include some molecular chaperones and some components 
of the UPP (62). Unfolded or misfolded polypeptides will either be folded into their 
native form or be degraded such as through UPP. Therefore these unwanted polypeptides 
will not cause toxicity to the cells (62). For example, Hsp70 and some of its associated 
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proteins serve as hinges to connect the chaperones machinery with UPP (179). Given the 
important roles of both chaperones and UPP in the polyglutamine diseases, it is 
reasonable to imagine that the link between them may have an intriguing impact on the 
folding and degradation of polyQ-expanded proteins and other proteins in these diseases.  
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Figure 3: Striatum of HD patients at different disease stages 
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Figure 6: Models of CBP/p300 function as transcription co-activators 
 
 
